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Does Living Donor Age Matter in Kidney
Transplantation?
Recent study results should encourage more donor
paired exchanges
By Tracy Hampton

A

cross the globe, numerous kidney transplant candidates and
donors are linking up in often
complicated ways to facilitate more
transplants through exchange programs, or swaps. The largest swap so
far, which was orchestrated by the
National Kidney Registry (NKR)
and involved 60 lives and 30 kidneys, was described recently in
The New York Times (http://www.
nytimes.com/2012/02/19/health/
lives-forever-linked-through-kidney-transplant-chain-124.html?_
r=2). Also, in early February the
NKR announced that it had facilitated
its 400th exchange transplant. These efforts by the NKR and other programs
could not come at a better time. Nearly
90,000 people in the United States are
waiting for a kidney transplant, and

many will die before a suitable organ
becomes available. The shortage is expected to worsen.
Such living donor chains and simpler
closed-loop paired exchanges, which involve two pairs of donors and recipients,
assume that kidneys from living donors
are of comparable quality and anticipated longevity. But how true is this
assumption? Potential recipients often
wonder, will the kidney received from a
stranger—particularly an older one—be
as good as a kidney donated by a loved
one?
“In a proposed kidney paired donation match, if an old donor–recipient
pair is matched to a young donor–recipient pair, the young recipient may
feel disadvantaged and may not be willContinued on page 2

By Tracy Hampton

A

But nonatherosclerotic conditions
such as cardiac failure, sudden cardiac
death, and arrhythmia are more common causes of cardiovascular events in
individuals with CKD than in the general population, and the bleeding risk
of antiplatelet agents may be greater
among people with CKD because of
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Antiplatelet Therapy in Patients with Chronic
Kidney Disease: Is It Safe?
ntiplatelet therapy that inhibits
blood clotting can be life-saving
for individuals at high risk for
cardiovascular disease or stroke. At first
glance, this should apply to patients
with chronic kidney disease (CKD),
who are more likely to die of cardiovascular disease than of any other cause.

Inside

impaired hemostasis.
Investigators recently published a review in the Annals of Internal Medicine
on the benefits and harms of antiplatelet agents in these patients, focusing on
cardiovascular events, mortality, and
bleeding.
“Until now, data from studies done
in the general population were extrapolated to people with chronic kidney
disease,” said senior author Giovanni
Strippoli, MD, PhD, who holds titles
at the school of public health at the
University of Sydney in Australia, the
Mario Negri Sud Consortium in Italy,
Continued on page 4
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Living Donor Age
Continued from page 1

ing to trade with an older donor,” said
Paolo Ferrari, MD, director of Australia’s national registry for paired kidney
exchanges. “Refusal to participate in an
exchange could break the chain of potential matches identified after a match
run and could limit the success of a kidney paired donation program.”
A recent study by John Gill, MD,
and his colleagues, of the University of
British Columbia, in Vancouver, Canada, that appears in the Clinical Journal

of the American Society of Nephrology
investigates this issue. The researchers
analyzed the survival of kidneys from
donors of different age groups that were
transplanted into recipients of different
age groups. Their study included data
from all adult kidney transplants from
living donors that were performed in the
United States from January 1988 to December 2003, with follow-up through
September 2007.

Age not an issue
The investigators found that except for
recipients aged 18 to 39, who benefited
the most when they received kidneys

from donors aged 18 to 39, donor age
between 18 and 64 had a minimal effect
on the survival of transplanted kidneys.
Specifically, the researchers noted a difference of only 1 to 2 years in allograft
half-life, with no graded association,
among different donor age groups.
“These findings show that in contrast
to deceased donor transplantation, the
age of a living donor has little impact
on transplant survival,” Gill said. “This
information should help increase participation and efficiency of living donor
paired exchange programs because it alleviates patient concerns about receiving
a kidney from an older aged living do-
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nor that currently limits acceptance of a
proposed transplant in paired exchange
programs.”
More experience is needed to determine the outcome of transplants from
living donors aged 65 and older relative
to younger living donors, Gill said.
In addition to expanding participation in exchange programs by blood
group and tissue-incompatible donor–
recipient pairs, the results may also encourage participation of more compatible donor–recipient pairs. Finally, the
information should prompt exchange
programs to reexamine any matching
algorithms that emphasize donor–recipient age matching.
“This study’s observation supports
data from the Australian registry, where
13.8 percent of live donors were aged
60 years or older, showing that live donor–recipient age difference does not
impact graft or patient survival,” said
Ferrari, who was not involved with the
study by Gill and his associates. Those
findings were published by Ferrari and
his colleagues in 2011 in Nephrology
Dialysis Transplantation.
“Taken together, these findings of
the two registry data are of major relevance for policy and decision making in kidney paired donation,” Ferrari said. They reinforce the view that
it is acceptable to ignore donor–donor
or donor–recipient age differences as
a scoring parameter in ranking match
combinations.”

Weighing options
Gill and his team also juxtaposed
their results against the probabilities
that wait-listed patients would receive
a kidney from a deceased donor and
their risk of being excluded from transplantation during the study because of
death or permanent removal from the
wait-list.
The probability of deceased donor
transplantation after 3 years of waitlisting ranged from 21 percent to 66
percent depending on patients’ blood
type and antibody levels, whereas the
probability of being excluded from
transplantation ranged from 6 percent
to 27 percent by age, race, and type of
kidney disease. Gill noted that when
patients consider these probabilities,
many will likely find that participating
in living donor paired exchanges—and
possibly receiving a kidney from an
older donor—is a better option than
continuing to wait for a deceased donor
transplant.
Yet the study included relatively few
living donors aged 60 and older, the
authors said, noting that there may be
certain patient subgroups who tolerate
dialysis relatively well, so that waiting
while they continue to receive dialysis
would be a reasonable consideration.
Also, they were unable to evaluate the
effect of other important donor factors
that may affect transplant survival and
confound the results, including predonation kidney function, donor blood
pressure, and diabetes in the donor.
The authors stressed that their find-

ings should not be interpreted as a dismissal of the importance of living donor age
on transplant outcomes. Most recipient
age groups with living donors between 40
and 64 had a small but statistically significant increased risk of allograft loss compared with those whose living donors were
18 to 39 years old, and in all recipient age
groups, the greatest donor age-associated
risk of allograft loss was among recipients
from living donors aged 65 and older. This
increased risk of allograft failure with older
donor age is consistent with results from
a recent single-center American Journal
of Transplantation publication from the
Mayo Clinic that showed an association
between living donor age and the risk of
death-censored graft loss. That study did
not show an association between living
donor age and patient death.
Although questions still remain about
the comparable quality of different do-

nors’ organs, the results shown by Gill and
his team provide valuable information to
transplant candidates and potential donors who are weighing their options.
Study co-authors include Peter Chang,
MD, Jagbir Gill, MD, James Dong,
Caren Rose, Howard Yan, MD, David
Landsberg, MD (University of British Columbia, in Vancouver, Canada); and Edward Cole, MD (University of Toronto, in
Canada).
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Paired Donations Increase
Scrutiny of Issues

K

idneys are the most commonly transplanted organ, and now
with the advent of transplant chains that use several sets
of matched pairs, the numbers of these logistically challenging
operations are poised to rise to levels unanticipated only a few
years ago. At the same time, increased scrutiny of chain transplants, which rely on living donors, is emerging from all corners
of the industry.
A recent conference of national and regional kidney transplant
partners represented a first attempt to agree on the direction of
their field. Insurers and representatives from several registries and
the large federally run United Network for Organ Sharing (UNOS)
also attended. UNOS manages the national transplant waiting list
and maintains the database that has all organ transplant data,
from every transplant that happens in the United States.
Held in late March in Herndon, VA, the Consensus Conference
on Kidney Paired Donation had an ambitious goal—to seek consensus among the 70 participants on ways to increase the volume of transplants that involve kidney paired donation (KPD). The
genesis of the conference was the idea that KPD is the most
effective approach to recruit a substantial pool of high-quality kidneys from healthy living donors. These donors would not have
volunteered otherwise because their kidneys weren’t a compatible match for their family member or loved one. Despite the need
and opportunities for this type of donation, KPD remains an often
unused option.
An announcement from the University of California, San Francisco—where the conference’s lead organizer Sandy Feng, MD, PhD,
is a transplant surgeon—described the first consensus meeting
and noted that “the emergence of multiple KPD programs with
diverse approaches and processes attests to a lack of consensus
as to how to maximize the benefit and minimize the risk of KPD.”
While the participants expressed a desire for a unified registry
that would provide a centralized system for storing and accessing
data about donors and recipients, they ultimately could not agree
over how this unifying effort would take place, according to Kevin
Sack, who reported on the conference for The New York Times.
One mathematician from the U.S. Naval Academy, Sommer
Gentry, who had been working on donation models, wanted to
eliminate barriers to a national registry. “With two pools of 100,
you get fewer opportunities than with one pool of 200,” to match
donors to recipients.
Sack noted that Feng was concerned that unifying all of the current registries into one system might stifle the innovations used
by successful registries like the National Kidney Registry. “Maybe
we can have different operations with common allocation methods and principles, [without complete unification of systems],”
Feng said.

Platinum Level
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Antiplatelet Therapy
Continued from page 3
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and Diaverum in Sweden. “Previous research from our group and others has
shown that such extrapolations could be
very dangerous, and interventions that
may be very good in the general population may have no effect or even be
harmful in people with chronic kidney
disease
Paying particular attention to patients with CKD while conducting clinical trials will only become more important. Approximately 10 percent to 15
percent of the adult population worldwide have the disease, and its prevalence
is on the rise because of increasing rates
of diabetes and obesity.

Analyzing available data
Mining Embase and Cochrane databases from 1980 through November 2011
without language restriction, Strippoli
and his colleagues selected randomized
trials that included adults with CKD
and compared antiplatelet agents with
standard care, placebo, or no treatment.
“Nephrology is lagging behind all
other disciplines of internal medicine
when it comes to randomized trials,
and a strong effort is needed to do more
trials and to summarize existing knowledge from the few small existing trials
that have been published,” said Strippoli. Many of the trials in the analysis were
not performed to study issues specifically in kidney disease but included a small
portion of people with the condition.
Nine trials (9969 participants) provided information on antiplatelet treatment among persons with CKD who
had acute coronary syndrome or were
undergoing coronary artery intervention and were considered at high risk
for subsequent vessel closure. All data
for these trials were post hoc analyses
for subgroups of participants with CKD
from larger trials. The trials provided
data for glycoprotein IIb/IIIa inhibitors
(abciximab, eptifibatide, or tirofiban)
or clopidogrel (two trials, 4498 participants), and all involved coadministration of aspirin with or without heparin.
The median follow-up time was 12
months.
Another 31 trials provided data
on 11,701 persons with stable or no
cardiovascular disease who received antiplatelet therapy. Twelve trials studied
antiplatelet effects on mortality, progression of kidney disease, or safety in
patients who had glomerulonephritis,
diabetic nephropathy, or an impaired
GFR regardless of cause. The agents
administered included aspirin, dipyridamole, aspirin and dipyridamole, or a
thienopyridine (clopidogrel or ticlopidine), and the median follow-up time
was 12 months. Seventeen of the trials
provided shorter-term data (median of
6 months of follow-up) for a variety of
antiplatelet treatments in persons who
were receiving or would soon require
dialysis. Four trials administered antiplatelet therapy to kidney transplant
recipients.

Pros and cons of anticlotting
drugs
In general, the investigators found that
the available information on antiplatelet
therapy in patients with CKD is of low or
very low quality, with considerable variation in trial duration, heterogeneity in
the definitions and assessment of bleeding outcomes, reliance on subgroup data
from major trials, and substantial methodologic limitations in data for patients
with stable cardiovascular disease.
The researchers reported low-quality
evidence that in people with acute coronary syndromes, glycoprotein IIb/IIIa
inhibitors or clopidogrel plus standard
care had little or no effect compared with
standard care alone on all-cause or cardiovascular mortality or on myocardial
infarction, but the treatments increased
serious bleeding by up to 40 percent.
Also according to generally low-quality
evidence, antiplatelet therapy prevented
myocardial infarction (lowering the risk
by about 34 percent) but caused uncertain effects on mortality and increased
minor bleeding by approximately 70 percent compared with placebo or no treatment in persons with stable or no cardiovascular disease.
These findings indicate that any benefits of antiplatelet therapy for people with
CKD are uncertain and are potentially
outweighed by bleeding hazards.
“All in all, these drugs should be used
with care and attention, as all doctors do,
and we should always think before we
prescribe,” said Strippoli. Also, he and
his coauthors noted that many patients
would not be likely to accept the risk for
major bleeding to reduce their risk for
myocardial infarction without proven
reductions in death or the need for coronary revascularization.
“This systematic review and metaanalyses primarily highlight the rather
limited evidence from existing randomized trials about the efficacy and safety of antiplatelet agents for preventing
cardiovascular events and death across
the spectrum of chronic kidney disease
and in those receiving dialysis or a renal
transplant,” said Alan Go, MD, who is
the director of the comprehensive clinical research unit and the regional medical
director for clinical trials at Kaiser Permanente Northern California and who was
not involved with the research.
Given the low quality of the available evidence, the investigators advocate
for specific trials evaluating antiplatelet
therapies, including newer agents, in individuals with CKD and coexisting acute
or stable cardiovascular disease. They also
note that no data are currently available
on antiplatelet use in dialysis patients or
kidney transplant recipients who have
acute coronary syndromes or require coronary artery revascularization.
“Given the risks of bleeding associated
with these agents, additional studies are
needed to delineate the net clinical benefit or harm at different levels of renal
function through randomized trials as
well as studies done in large, diverse clinical practice populations that are more
representative,” said Go.
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ASN Cosponsors Congressional Briefing on Racial
Disparities in Kidney Disease

K

idney disease affects millions
in the United States across all
populations, but it is more
common among minorities. African
Americans, Hispanics, Pacific Islanders, and Native Americans face a disproportionately increased risk for developing kidney disease.
Broadening knowledge about the
disparities in kidney care that minorities confront is essential to resolving those disparities. On April
19, 2012, the American Society of
Nephrology (ASN), Dialysis Patient
Citizens (DPC), and the National
Urban League led a congressional
briefing on kidney health disparities.
Maria Cristina Arce, MD, and Neil
R. Powe, MD, addressed members
of Congress and Capitol Hill staffers about this critical issue on ASN’s
behalf.
A nephrology fellow at Stanford
University School of Medicine, Arce
presented information on kidney
disease in the Hispanic population.
She noted that Hispanic ethnicity
is associated with an increased risk
for end stage renal disease (ESRD)
compared with whites—an increase
not explained by higher prevalence
of diabetes or by diabetes severity. In
addition, a higher number of younger
Hispanics are starting dialysis, possibly due to worsening rates of obesity, earlier onset of diabetes and hypertension, and faster progression of
kidney disease. Hispanics are 15 percent less likely to use arteriovenous
access for their first hemodialysis session, Arce said.
Powe spoke to the audience at
the congressional briefing about the
many factors that contribute to a
rate of kidney failure in minorities
that is up to four times greater than
in whites. Chief of Medicine at San
Francisco General Hospital and ViceChair of Medicine at the University
of California San Francisco, Powe
noted that kidney disease occurs
more often in minorities and starts
earlier. Socioeconomic status, lifestyle and quality of care explain 44
percent of the threefold excess risk of
chronic kidney disease (CKD) in African Americans compared to whites.
African Americans are also much
less likely to get transplants or to be
placed on the transplant waiting list,
said Powe. His presentation echoed
Arce’s findings that minorities in the
United States are referred to nephrologists much later than whites.
Powe emphasized to lawmakers
the current and future opportunities
for the federal government to ad-

dress racial and ethnic disparities in
kidney care. These include comparative effectiveness studies of treatment
in minorities, enhanced patient and
provider education, and increasing
support for demonstration projects to
assess the effectiveness of changes in
health care.
DPC board member Eric Edwards
spoke
to those assembled about liv7" x 10"

ing with kidney disease. Also presenting at the briefing were Kafui Agbemenu, Health Advocate for the Urban
League, who spoke about how the
Urban League in Pittsburgh is improving minority access to health
care. Dana Atwater of Baxter Healthcare presented general information
on CKD in the United States.
The American Society of Neph-
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• In controlled clinical trials, ESAs increased the risk of death in patients
undergoing coronary artery bypass graft surgery (CABG) and deep venous
thrombosis (DVT) was observed in patients undergoing orthopedic procedures.
The design and overall results of 3 large trials comparing higher and lower
hemoglobin targets are shown in Table 2 (Normal Hematocrit Study (NHS),
Correction of Hemoglobin Outcomes in Renal Insufficiency (CHOIR) and Trial
to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT)).
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rology supports a variety of efforts
to address and resolve disparities in
kidney care in the United States and
worldwide, including support of Senate bill 2163 that promotes research
regarding disparities and access to
care. ASN encourages members to
contact your members of Congress
to support this bill at http://capwiz.
com/asn/home.

Table 2 Adverse Cardiovascular Outcomes in Randomized Controlled Trials
Comparing Higher and Lower Hemoglobin Targets in Patients with CKD
NHS
(N = 1265)
1993 to 1996

CHOIR
(N = 1432)
Time Period of Trial
2003 to 2006
Patients with CKD
Patients with CKD
not on dialysis with
on hemodialysis
hemoglobin
with coexisting CHF
Population
< 11 g/dL
or CAD, hematocrit
not previously
30 ± 3% on
administered
epoetin alfa
epoetin alfa
Hemoglobin Target;
Higher vs. Lower
14.0 vs. 10.0
13.5 vs. 11.3
(g/dL)
Median (Q1, Q3)
12.6 (11.6, 13.3) 13.0 (12.2, 13.4)
Achieved Hemoglobin
vs.
vs.
level (g/dL)
10.3 (10.0, 10.7) 11.4 (11.1, 11.6)
Primary Endpoint

TREAT
(N = 4038)
2004 to 2009
Patients with
CKD not on
dialysis with
type II diabetes,
hemoglobin
≤ 11 g/dL
13.0 vs. ≥ 9.0

12.5 (12.0, 12.8)
vs.
10.6 (9.9, 11.3)
All-cause mortality,
All-cause mortality,
All-cause mortality
MI, myocardial
MI, hospitalization
or non-fatal MI
ischemia, heart
for CHF, or stroke
failure, and stroke

Hazard Ratio or
Relative Risk
1.28 (1.06 – 1.56) 1.34 (1.03 – 1.74) 1.05 (0.94 – 1.17)
(95% CI)
Adverse Outcome for
All-cause mortality All-cause mortality
Stroke
Higher Target Group
Hazard Ratio or
Relative Risk
1.27 (1.04 – 1.54) 1.48 (0.97 – 2.27) 1.92 (1.38 – 2.68)
(95% CI)
Patients with Chronic Kidney Disease Not on Dialysis
OMONTYS is not indicated and is not recommended for the treatment of anemia
in patients with CKD who are not on dialysis.
A higher percentage of patients (22%) who received OMONTYS experienced a
composite cardiovascular safety endpoint event compared to 17% who received
darbepoetin alfa in two randomized, active-controlled, open-label, multi-center
trials of 983 patients with anemia due to CKD who were not on dialysis. The trials
had a pre-specified, prospective analysis of a composite safety endpoint consisting
of death, myocardial infarction, stroke, or serious adverse events of congestive
heart failure, unstable angina or arrhythmia (hazard ratio 1.32, 95% CI: 0.97, 1.81).
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence
in Patients with Cancer receiving ESAs
OMONTYS is not indicated and is not recommended for reduction of RBC
transfusions in patients receiving treatment for cancer and whose anemia is not
due to CKD because ESAs have shown harm in some settings and the benefit-risk
factors for OMONTYS in this setting have not been evaluated.
The safety and efficacy of OMONTYS have not been established for use in patients
with anemia due to cancer chemotherapy. Results from clinical trials of ESAs
in patients with anemia due to cancer therapy showed decreased locoregional
control, progression-free survival and/or decreased overall survival. The findings
were observed in clinical trials of other ESAs administered to patients with: breast
cancer receiving chemotherapy, advanced head and neck cancer receiving radiation
therapy, lymphoid malignancy, cervical cancer, non-small cell lung cancer, and
with various malignancies who were not receiving chemotherapy or radiotherapy.
Hypertension
OMONTYS is contraindicated in patients with uncontrolled hypertension.
Appropriately control hypertension prior to initiation of and during treatment with
OMONTYS. Reduce or withhold OMONTYS if blood pressure becomes difficult to
control. Advise patients of the importance of compliance with antihypertensive
therapy and dietary restrictions.
Lack or Loss of Response to OMONTYS
For lack or loss of hemoglobin response to OMONTYS, initiate a search for
causative factors (e.g., iron deficiency, infection, inflammation, bleeding). If
typical causes of lack or loss of hemoglobin response are excluded, evaluate
the patient for the presence of antibodies to peginesatide. In the absence of
antibodies to peginesatide, follow dosing recommendations for management
of patients with an insufficient hemoglobin response to OMONTYS therapy.
Contact Affymax, Inc. (1-855-466-6689) to perform assays for binding and
neutralizing antibodies.
Dialysis Management
Patients may require adjustments in their dialysis prescriptions after initiation of
OMONTYS. Patients receiving OMONTYS may require increased anticoagulation
with heparin to prevent clotting of the extracorporeal circuit during hemodialysis.
Laboratory Monitoring
Evaluate transferrin saturation and serum ferritin prior to and during OMONTYS
treatment. Administer supplemental iron therapy when serum ferritin is less
than 100 mcg/L or when serum transferrin saturation is less than 20%. The
majority of patients with CKD will require supplemental iron during the course
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Kidney Disease and Minorities in the United States
• Minorities are more likely to receive a late evaluation by a nephrologist
• Minorities in the United States with CKD are more likely to have uncontrolled blood pressure
• African Americans with kidney disease are 3.6 times more likely to progress to kidney failure than
whites, and six times more likely to develop kidney failure related to hypertension
• Hispanics and Native Americans are approximately two times more likely to progress to kidney failure
than whites
• African Americans are more likely to receive hemodialysis, and less likely to receive peritoneal dialysis
and a transplant
• African Americans are less likely to be waitlisted for and receive a kidney transplant
• Research, education, and clinical care focused on prevention can help eliminate disparities in kidney
disease
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of ESA therapy. Following initiation of therapy and after each dose adjustment,
monitor hemoglobin every 2 weeks until the hemoglobin is stable and sufficient
to minimize the need for RBC transfusion. Thereafter, hemoglobin should be
monitored at least monthly provided hemoglobin levels remain stable.
ADVERSE REACTIONS
The following serious adverse reactions observed during clinical trials with
OMONTYS are discussed in greater detail in other sections of the labeling:
• Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism
[see Warnings and Precautions]
• Hypertension [see Warnings and Precautions]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse
reaction rates observed in the clinical studies of OMONTYS cannot be directly
compared to rates in the clinical trials of other drugs and may not reflect the
rates observed in practice.
Patients with Chronic Kidney Disease
Adverse reactions were determined based on pooled data from two active
controlled studies of 1066 dialysis patients treated with OMONTYS and
542 treated with epoetin, including 938 exposed for at least 6 months and
825 exposed for greater than one year to OMONTYS. The population for
OMONTYS was 20 to 93 years of age, 58.5% male, and the percentages of
Caucasian, Black (including African Americans), and Asian patients were 57.9%,
37.4%, and 3.1%, respectively. The median weight adjusted dose of OMONTYS
was 0.07mg/kg and 113 U/week/kg of epoetin.
Table 3 summarizes the most frequent adverse reactions (≥ 10%) in dialysis
patients treated with OMONTYS.
Table 3 Adverse Reactions Occurring in ≥10% of Dialysis Patients treated
with OMONTYS
Adverse Reactions

Dialysis Patients
Treated with
OMONTYS
(N = 1066)

Gastrointestinal Disorders
Diarrhea
18.4%
Nausea
17.4%
Vomiting
15.3%
Respiratory, Thoracic and Mediastinal Disorders
Dyspnea
18.4%
Cough
15.9%
Injury, Poisoning and Procedural Complications
Arteriovenous Fistula
16.1%
Site Complication
Procedural Hypotension
10.9%
Nervous System Disorders
Headache
15.4%
Musculoskeletal and Connective Tissue Disorders
Muscle Spasms
15.3%
Pain in Extremity
10.9%
Back Pain
10.9%
Arthralgia
10.7%
Vascular Disorders
Hypotension
14.2%
Hypertension
13.2%
General Disorders and Administration Site Conditions
Pyrexia
12.2%
Metabolism and Nutrition Disorders
Hyperkalemia
11.4%
Infections and Infestations
Upper Respiratory Tract Infection
11.0%

Dialysis Patients
Treated with
Epoetin
(N = 542)
15.9%
19.6%
13.3%
19.4%
16.6%
16.6%
12.5%
15.9%
17.2%
12.7%
11.3%
9.8%
14.6%
11.4%
14.0%
11.8%
12.4%

Seizures have occurred in patients participating in OMONTYS clinical studies. During
the first several months following initiation of OMONTYS, blood pressure and the
presence of premonitory neurologic symptoms should be monitored closely.
Advise patients to contact their healthcare practitioner for new-onset seizures,
premonitory symptoms, or change in seizure frequency.
Allergic reactions have been reported in patients treated with
OMONTYS. Discontinue OMONTYS and administer appropriate therapy if a
serious allergic, anaphylactic or infusion-related reaction occurs.
Immunogenicity
Of the 2357 patients tested, 29 (1.2%) had detectable levels of peginesatidespecific binding antibodies. There was a higher incidence of peginesatide-specific
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binding antibodies in patients dosed subcutaneously (1.9%) as compared to
those dosed intravenously (0.7%). Peginesatide neutralizing antibodies were
detected in vitro using a cell-based functional assay in 21 of these patients
(0.9%). In approximately half of all antibody-positive patients, the presence of
antibodies was associated with declining hemoglobin levels, the requirement for
increased doses of OMONTYS to maintain hemoglobin levels, and/or transfusion
for anemia of CKD. No cases of pure red cell aplasia (PRCA) developed in
patients receiving OMONTYS during clinical trials.
DRUG INTERACTIONS
No formal drug/drug interaction studies have been performed. Peginesatide does
not bind to serum albumin or lipoproteins as demonstrated in in vitro protein
binding studies in rat, monkey and human sera. In vitro studies conducted with
human hepatocytes or microsomes have shown no potential for peginesatide
to induce or inhibit CYP450 enzymes.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category C
There are no adequate and well-controlled studies in pregnant women.
Peginesatide was teratogenic and caused embryofetal lethality when
administered to pregnant animals at doses and/or exposures that resulted in
polycythemia. OMONTYS should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.
Administration of peginesatide by intravenous injection to rats and rabbits during
organogenesis was associated with embryofetal toxicity and malformations.
Dosing was every third day in rats for a total of 5 doses and every fifth day
in rabbits for a total of 3 doses (0.01 to 50 mg/kg/dose). In rats and rabbits,
adverse embryofetal effects included reduced fetal weight, increased resorption,
embryofetal lethality, cleft palate (rats only), sternum anomalies, unossification
of sternebrae and metatarsals, and reduced ossification of some bones.
Embryofetal toxicity was evident in rats at peginesatide doses of ≥ 1 mg/kg
and the malformations (cleft palate and sternoschisis, and variations in blood
vessels) were mostly evident at doses of ≥ 10 mg/kg. The dose of 1 mg/kg
results in exposures (AUC) comparable to those in humans after intravenous
administration at a dose of 0.35 mg/kg in patients on dialysis. In a separate
embryofetal developmental study in rats, reduced fetal weight and reduced
ossification were seen at a lower dose of 0.25 mg/kg. Reduced fetal weight
and delayed ossification in rabbits were observed at ≥ 0.5 mg/kg/dose of
peginesatide. In a separate embryofetal developmental study in rabbits, adverse
findings were observed at lower doses and included increased incidence of fused
sternebrae at 0.25 mg/kg. The effects in rabbits were observed at doses lower
(5% - 50%) than the dose of 0.35 mg/kg in patients.
Nursing Mothers
It is not known whether peginesatide is excreted in human milk. Because
many drugs are excreted into human milk, caution should be exercised when
OMONTYS is administered to a nursing woman.
Pediatric Use
The safety and efficacy of OMONTYS in pediatric patients have not
been established.
Geriatric Use
Of the total number of dialysis patients in Phase 3 clinical studies of OMONTYS,
32.5% were age 65 and over, while 13% were age 75 and over. No overall
differences in safety or effectiveness were observed between these subjects
and younger subjects.
OVERDOSAGE
OMONTYS overdosage can elevate hemoglobin levels above the desired level,
which should be managed with discontinuation or reduction of OMONTYS
dosage and/or with phlebotomy, as clinically indicated. Cases of severe
hypertension have been observed following overdose with ESAs [see Warnings
and Precautions].
PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Medication Guide).
Marketed by:
Affymax, Inc.
Palo Alto, CA 94304
Distributed and Marketed by:
Takeda Pharmaceuticals America, Inc.
Deerfield, IL 60015
For more detailed information, see the full prescribing information for OMONTYS
at www.omontys.com or contact Takeda Pharmaceuticals America, Inc.
OMONTYS is a trademark of Affymax, Inc. registered in the U.S. Patent and
Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.
All other trademarks are the property of their respective owners.
©2012 Takeda Pharmaceuticals America, Inc.
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T

welve quality measures aimed
at improving care for patients
with kidney disease were recently endorsed by the National Quality Forum (NQF). The metrics cover
several areas of renal care, including
anemia, dialysis adequacy, and vascular
access. “These measures will help ensure
renal patients receive safe, high-quality,
and compassionate care throughout the
course of treatment,” said the president
and CEO of NQF, Janet Corrigan,
PhD, MBA.
Thirty-three possible measures for
renal care were evaluated and then narrowed to the 12 endorsed by the NQF
board of directors. Three new measures—for anemia and cardiovascular
disease in patients with kidney disease—were added to the nine metrics
previously endorsed by NQF.
The NQF renal quality measures
pertain to aspects of care for patients
with chronic kidney disease, end stage
renal disease, and those undergoing dialysis. They include the serum phosphorus concentration in dialysis patients,
metrics targeted at reducing the use of
catheters and increasing the use of arteriovenous fistulas in vascular access
for hemodialysis, and a risk-adjusted
standardized mortality ratio for dialysis
facilities.
Created to improve health care quality, the NQF works to find consensus on
national goals for performance improvement, endorses standards for measuring
performance, and promotes these goals
through education and outreach. The
NQF kidney disease criteria were determined in collaboration with several
stakeholders including the Centers for
Medicare & Medicaid Services, Kidney
Care Quality Alliance, and the American Medical Association Physician Consortium for Performance Improvement
Members of the kidney community
have until May 1, 2012, to appeal any
of the 12 endorsed quality measures
before final approval by NQF.

Kidney 2.0

More and more, the world depends on
electronic information. The Internet has
changed how we communicate, learn,
and discover. In this issue of Kidney
News, a series of articles explores the
impact of the Internet on nephrology.
Dealing with a deluge of information?
Looking for new ways to connect?
We have some answers.

The New World of Medical Tweeting
By Afreen I. Shariff, MD, and Tejas Desai, MD

T

witter has taken the world by storm. No one
could have predicted that just 6 years after its
inception Twitter would have 300 million users
generating 300 million messages every day (1). If you are
among the uninitiated, you should become familiar with
how Twitter works and why it’s one of the most popular
micro-blogging websites in the world.
Twitter is an open forum for sharing real-time information through “tweets.” A tweet is a short message of 140 characters or less that can convey absolutely
anything to your “followers” (people who subscribe to
your “feed” of tweets). And with Twitter you aren’t just
limited to text. Using third-party providers, you can
insert Web addresses and link to photos, videos, and
more. If you like a message you can copy and paste it
to your followers, or in Twitter parlance “retweet it,”
which is how a message is amplified. A recent study
found that although 40 percent of messages on Twitter
were pointless babble, 38 percent were conversational—transferring information and spreading content
(2).
The popularity of Twitter with the media, celebrities,
and public figures is well documented, but members
of the medical community seem hesitant to associate
themselves with it. There could be many reasons for this:
physicians may be unaware or unfamiliar with Twitter,
they may be too busy, or they may fear potential privacy
issues (3). Anticipating this, the American Medical Association has released a public statement about professionalism in social media:
“Participating in social networking and other
similar internet opportunities can support physicians’ personal expression, enable individual physicians to have a professional presence online, foster
collegiality and camaraderie within the profession,
provide opportunity to widely disseminate public
health messages and other health communication. Social networks, blogs, and other forms of
communication online also create new challenges
to the patient-physician relationship. Physicians
should weigh a number of considerations when
maintaining a presence online.”(4)

Because Twitter is a large pool of raw information and
opinions, there are networking opportunities for those
who can tap its potential. The news media analyze Twitter posts to gain insights into elections, and politicians
focus campaigns based on public sentiment sifted from
the site (5). This concept can be used in medical conferences for networking within the medical community and
with patients. Journals and conferences, including the
American Society of Nephrology (ASN) Kidney Week,
want to reach the widest possible audience, and using the
large platform and audience Twitter provides ensures their
important information is carried far and wide. By analyzing Twitter messages sent with conference or journal
“hashtags” (short unique identifiers starting with “#”),
it is possible to identify and understand patterns and
how these impact a message’s reach. During ASN Kidney Week 2011, we identified 172 unique tweeters who
produced 993 tweets. Analysis of the content, citation,
and sentiment have led to some interesting findings about
conference-based tweeting and ways to improve conferences’ impact and popularity.
This opens a door to advanced medical informatics where physicians can interact with patients and
network with consultants, students, and prospective
residents. Twitter has many potential health care applications, such as recruiting potential organ donors,
creating online communities for families with special
needs, reporting new advances in therapy, initiating
clinical case discussions among attending physicians
and residents, and health marketing.
In a recent JAMA study (6), investigators analyzed
5156 tweets from physician accounts and found a majority (78 percent) identified themselves with their full
name, with surgeons occupying the top spot for the
highest number of tweets (39 percent) closely followed
by internal medicine (29 percent). Physicians holding
MDs (70.2 percent) were also more likely to tweet than
their DO friends (2 percent) (6). Another group of
researchers followed 125 students over a semester and
found that those students in the Twitter-based education group were more engaged in the subject and scored
better than their other classmates (7). These data suggest
that Twitter can be a strong educational tool. Research-

ers at East Carolina University are studying the use of
Twitter to communicate during conferences and are
developing strategies to better engage the student and
physician populations.
In summary, Twitter has the power to spread knowledge and engage many people in conversations. It is the
best one-to-many communication system to build your
brand, network, give advice, or just have fun. Especially
in an age of shrinking health care budgets, Twitter is an
effective solution to the need for cheap mass communication (8). With Twitter, the future of communications
is here, and it’s both free and easy.
Afreen I. Shariff, MD, is with the department of internal
medicine and Tejas Desai, MD, is with the division of nephrology and hypertension, at East Carolina University in
Greenville, NC.
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How to Deal with Information Overload
By Walter Jessen, PhD, and Simon Frantz

S

uffering from information overload
is a frustrating and all-too-common condition today. If it isn’t hard
enough to clear your overflowing email
inbox, there’s the stress of staying on top
of the blossoming number of journals
and medical blogs in your field, papers
uncovered through regular PubMed or
Medline searches, not to mention the
pressure of keeping up-to-date with the
latest must-use social media tools. And
yet, a small number of people seem to
stay afloat while the vast majority of us
are drowning in information. What’s
their secret?
Every year, the Science Online conference in North Carolina brings together some of the most savvy digital natives
in science and journalism. This provided
a perfect opportunity for us to pose the
question in the session Drowning in
Information! How Can We Create Organization & Balance—Tools and Strategies for Managing Information Overload
(Science and Otherwise) (http://scio12.
wikispaces.com/D3S2d.+Drowning+in+
Information). Below are some of the
main themes and tips that emerged for
managing the data deluge that hits you
on a daily basis.

Find signals among the noise
You don’t need to subscribe to everything! Find the information gathering
tools that suit your content needs. If
you regularly read journals and magazines, subscribe to their RSS feeds so
that you can read them all in one place.
Google Reader (www.google.com/
reader) is a free, Web-based aggregator
that allows you to organize, read, and
search all of your favorite news sites and
blogs in one place. If you like staying on
top of the latest trends in a particular
discipline, join Twitter (https://twitter.
com) and follow people in your field
and/or people that share your interests
and have your news curated. If you have
an iPhone or iPad, the Flipboard app
(http://flipboard.com) collates content
from several social media sources.

Filter, filter, filter
For many people, reading and responding to email consumes the most time
during a normal business day. Take
back some of the time used to manage
email by using folders to stay organized. In your email client, create specific
folders based on topic, task, or person.
Whether it’s for must-read content or

for messages you can turn to at a later
date, automate the task of sorting email
based on keyword(s) and/or sender. This
allows you to immediately focus on the
message rather than on the action of
sorting. Color-code emails to distinguish family and friends from meeting
requests or table of content alerts, and
do the same for RSS feeds, Twitter, and
other online sources. Divide information flows into folders or lists, such as
“Daily reads” or “Weekend reads” or
other categories that reflect your desired
reading habits and content organization. For more advanced management
between different services and devices,
use ifttt (If This Then That; http://ifttt.
com), which enables the creation of customized, automated tasks.

Organize and archive
There are numerous free online tools
that can help you store your information, but three repeatedly came up in
the discussion: Dropbox (https://www.
dropbox.com), which allows you to
share files between your work and home
computer; Mendeley (http://www.mendeley.com), a reference manager that allows you to organize, read, and annotate
PDF documents; and Evernote (http://

www.evernote.com), a note-taking app
which saves your most valuable notes,
clippings, and photos on your computer and across all your mobile devices.
Pinboard (http://pinboard.in) was also
mentioned; although it is a paid service
it allows you to bookmark and organize
links, effortlessly saving those shared via
Twitter.

Get into the habit
It’s easy to give up on a tool within days,
especially if it becomes stressful to deal
with its backlog after a deadline, conference or, heaven forbid, a vacation.
People recommended throwing yourself
into a method for 30 days and see if it
works before ditching it. And try regular cleansing sessions—for instance, try
clearing your information streams every
Sunday evening. That way, you’ll start
each week without the pressure or guilt
of looking at old content that you are
unlikely to read anyway.
Walter Jessen is a computational biologist,
knowledge curator, and Web developer at
Walter Jessen Discovery New Media (http://
www.walterjessen.com). Simon Frantz is
the Science/Technology Features editor at
BBC Future (http://www.bbc.com/future).

Doximity
By Sara Reistad-Long

T

he Journal of the American Medical Association has reported that one in
nine Americans now have chronic kidney disease, and that figure is believed to be growing. At the same time many publications (among them,
Kidney News) are tracking a drop in the number of nephrologists entering the
field, and others have documented the strain on those already practicing as dialysis resources are stretched thin.
As awareness of kidney disease within the general population increases, so will nephrologists’
need for a safe, efficient, and Health Insurance
Portability and Accountability Act (HIPAA)–
compliant system for securely managing incoming referrals and discussing patient information
with a treatment team. Although doctors themselves are often early adopters of information
technology—81 percent now own a smartphone,
for example—medicine as a whole has been slow
to catch up. Email and Short Message Service
(SMS), for instance, are not considered HIPAA
secure, a point that the Joint Commission on Accreditation of Healthcare Organizations emphasized in November 2011 when it
issued a ban on texting. This, of course, leaves physicians reliant on telephones,
pagers, and faxes to communicate patient information.
Doximity was founded to address what we see as one of the next big challenges in health care—facilitating communication among physicians. Our company
has been described as a kind of LinkedIn for doctors, and with nearly 30,000
physicians signed up, we’re already the largest medical professional network in
the country. Enabling doctors to find and make connections in their practices
and with alumni is valuable in itself, but what may be even more essential to our

specific community is a private and HIPAA-secure method
of exchanging information. We assign dual passwords to
each user so each message is encrypted end to end. And
because Doximity has been optimized for both smartphones and tablets, messages can be sent, and referrals made, from the operating
room—or far from the nearest hospital—as easily as from a computer.
Equally integral to safe communication is real-name interaction. At Doximity, we verify each of our users. We believe that ensuring every member’s identity
creates a framework of trust, expertise, and professionalism that reflects the effective physician interaction in the real world. The difference, of course, is that
these communications are increasingly happening as ongoing written discussions
across thousands of miles.
In many ways, our newest feature, iRounds, grew out of these changes. Not
unlike social networking sites such as Twitter, Facebook, and Google, iRounds
allows users to tap into larger communities to discuss patient cases, new research,
emerging medical technologies, and more.
“Doximity offers an easy way to keep up to date on the latest news, best
blog posts, and journal articles from our specialty,” said Joshua Schwimmer,
MD, a nephrologist at Lenox Hill Hospital and The Mount Sinai Hospital in
New York. “For example, a review article on focal segmental glomerulosclerosis
(FSGS) in the New England Journal of Medicine was the basis for a discussion
among multiple specialties about the presentation of FSGS, the differences
between FSGS and diabetic nephropathy, and the indications for renal biopsy.
The easy-access via smartphone and the Web, the user-friendly design, and the
ready availability of physicians’ credentials makes it simple to collaborate and
learn from your colleagues.”
Sara Reistad-Long is affiliated with Doximity.
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Understanding Research Impact
By Kristi L. Holmes and Cathy C. Sarli

U

nderstanding the true value of a
scholar’s research and output is
no small feat. Although it’s fairly
straightforward to track the number of
publications or total dollar amount of
awarded funding, it can be a greater challenge to assess the reach of scholarly efforts
and determine how others are utilizing
the research results. Metrics for assessing
research performance, quality, and impact
cover a wide range of the scholarly ecosystem and are used for a variety of purposes:
individual career planning, promotion,
and tenure; benchmarking to track group
or institutional performance; marketing
and strategic planning purposes; and reporting research outcomes to the public.

Author-level metrics
Author-level metrics allow individuals to
track their scholarly output and serve as
a reflection of a researcher’s productivity.
Enumerating such things as the number
of publications in the scholarly literature,
number of books published, and number
and amount of funding awards can all serve
to understand the efforts of individual researchers. One commonly used metric is
the Hirsch index (h index). The h index,
developed by Jorge E. Hirsch, PhD, in
2005 (1), offers a numeric index to measure the productivity and impact of a given
researcher. The h index is a quantitative
metric based on analysis of publication
data, using publications and citations to
provide “an estimate of the importance,
significance, and broad impact of a scientist’s cumulative research contributions”
(1). According to Hirsch, the h index is
defined as follows: “A scientist has index h
if h of his or her Np papers have at least h
citations each and the other (Np – h) papers have ≤h citations each” (1), where Np
is total number of papers published.
As an example, an h index of 10 means
that among all publications by one author,
10 of these publications have received at
least 10 citations each. The h index is but
one metric for author-level assessment.

No single metric is sufficient for measuring performance, quality, or impact by an
author; indeed, the discovery of a scholar’s
most impactful work may be gleaned only
through qualitative forms of assessment
that do not rely solely on publication data.

Article-level metrics
Citation counts are perhaps the most frequently used metric at the article level. A
citation is a reference to a specific publication. The inherent assumption is that
significant articles will have high numbers
of citations. Further analysis is required to
discover why select publications garner a
higher citation rate than others. Many databases provide tools for authors to track
citations to their work, with some offering
citation maps that can be downloaded for
reporting purposes.
A growing article-level metric is based
on the usage of a publication; several journals and third-party service providers are
making it possible to assess the Web-based
use and subsequent dissemination of individual articles. The Public Library of Science (PLoS) journals offer perhaps the most
highly developed publisher-based platform
for this type of tracking. Articles published
in PLoS journals include an article-level
metrics tab that shows such details as article usage statistics (e.g., HTML page views,
PDF and XML downloads, and accesses
from PubMed Central; number of users
via Mendeley; and number of Facebook
mentions); citations from the scholarly literature (currently from CrossRef, PubMed
Central, SciVerse Scopus, and Web of Science); social bookmarks from CiteULike
and Connotea; PLoS reader evaluation
(i.e., readers’ feedback on the article in the
form of comments, notes, and star ratings);
and discussion of the article in blogs (2).
These alternative metrics (or “altmetrics” as
they are commonly known) for articles and
even datasets and presentations are becoming easier to track via Web services such as
Total-Impact (http://total-impact.org) and
Altmetric (http://www.postgenomic.com),
who offers explorer and browser-based
bookmarklet applications.

Journal-level metrics
Journals are also assessed by different criteria. The impact factor, listed in Thomson
Reuters’ Journal Citation Reports, assigns
journals a numeric score based on the frequency with which the average article in the
journal is cited over a set period of time (3).
Whereas the impact factor tracks straight
citations, the Eigenfactor score (http://
www.eigenfactor.org) is derived from a formula based on citations from a journal over
a 5-year period, with citations from highly
ranked journals given more weight. Journal
self-citations are not included in the Eigenfactor score, unlike the impact factor score.
A caveat of note for journal-level metrics: specialized journals or those published
by societies may disseminate your work
more efficiently to colleagues in your field
than a “high-impact” general-interest science journal. Reaching your intended audience is the surest way to enhance the visibility and impact of your research.

Going beyond the metrics: the
Becker model
It is tempting to use these metrics as an
objective way to assign value or worth to a
researcher’s output or to an individual journal. Although these metrics can be helpful
in understanding research efforts, they cannot be evaluated in a vacuum. To understand the true impact of research, metrics
derived from publication data must be
supplemented with indicators that demonstrate tangible outcomes such as clinical
implementation, benefit to the community, influence on legislation or policy, and
economic benefit. Publication data alone
do not provide a full narrative of research
impact, nor are they predictive of meaningful health outcomes.
The Becker Medical Library Model for
Assessment of Research Impact (4,5) serves
as a framework to quantify and document
research impact based on research outputs
and activities. It includes resources for locating evidence of research impact and

strategies for enhancing research impact.
The site offers reporting templates, a glossary, and examples of relevant indicators of
impact across the research process as well as
a sample of a completed report. The use of
publication data in tandem with the Becker Model provides a more robust overview
of the impact of research to accomplish a
host of higher-order activities that are critical in today’s biomedical research world,
including the following:
• Justification of future requests for funding
• Quantification of return on research investment
• Discovery of how research findings are
being used
• Promotion and tenure activities
• Identification of possible collaborators
• Demonstration that research findings are
resulting in meaningful health outcomes
• Discovery of community benefit as a
result of research findings
1. Hirsch JE. An index to quantify an
individual’s scientific research output. Proc Natl Acad Sci U S A 2005;
102:16569–16572.
2. Public Library of Science. Articlelevel metrics. http://article-levelmetrics.plos.org.
3. Thomson Reuters. The Thomson Reuters impact factor. http://thomsonreuters.
com/products_services/science/free/essays/impact_factor.
4. Sarli CC, Dubinsky EK, Holmes KL.
Beyond citation analysis: a model for
assessment of research impact. J Med
Libr Assoc 2010; 98:17–23.
5. Bernard Becker Medical Library. Assessing the impact of research. The
Becker Medical Library Model for assessment of research impact. https://
becker.wustl.edu/impact/assessment/
index.html.
Kristi L. Holmes and Cathy C. Sarli are affiliated with the Bernard Becker Medical Library, School of Medicine, Washington University, St. Louis.
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Strategies to Enhance the Impact
of Your Research
Improving access to, and retrieval of, your research articles is the surest way to enhance their
impact. Repetition, consistency, and an awareness of the intended audience form the basis of
most of the following strategies in areas related to preparation for publication, dissemination
of content, and keeping track of your research.

1. Authors should use the same variation of their
name consistently throughout their academic careers. If your name is a common one, consider adding your full middle name to distinguish it from
other authors. Consistency enhances retrieval.
2. Consider adding the name of the research study
or your center, institute, division, or program as a
corporate author, and use the same name consistently. This will allow for enhanced retrieval of publications generated by a particular research study or
center, institute, division, or program in a database
or resource search. See the National Library of
Medicine’s Fact Sheet: Authorship in MEDLINE (1).
3. Assign Medical Subject Headings (MeSH) terms
to the manuscript. Contact your health sciences
library for assistance with MeSH terms.
4. Formulate a concise, well-constructed title and
abstract. Include crucial key words in the abstract.
See Wiley-Blackwell’s Optimizing Your Article for
Search Engines (2).
5. Retain the rights to your manuscripts to allow for
maximum flexibility in reusing your work.
6. If your work involves potential translational medicine applications, include a discussion of how the
research could translate to clinical outcomes. “Impact of journal articles will be improved if they
provide a direct line of reasoning for how findings
might translate into useful information for realworld behaviors or technologies. This will enhance
the probability that the article will affect public
policy and thus increase its impact.” (3)
7. Submit the manuscript to a digital subject repository or your institution’s facility, if they have one.
Contact your health sciences library for assistance
with identifying appropriate locations.
8. Publish your work in an open access journal. Open
access journals allow authors to retain rights to
their work, which allows for other options for dissemination of the research. Open access articles
may garner greater impact than traditional publication models (4).
9. Set up a website devoted to the research project,
and post manuscripts of publications, conference
abstracts, and supplemental materials—such as images, illustrations, slides, specimens, and progress
reports—on the site.
10. Share the research data and deposit it in appropriate repositories, such as GenBank (http://www.
ncbi.nlm.nih.gov/genbank) and other databases at
the National Center for Biotechnology Information, or with journal publishers willing to post the
data. Sharing of this information may lead to more
rapid analysis and identification of genetic contributions to diseases and medical conditions. One
study (5) has demonstrated a correlation between
shared research data and an increased number of
citations.
11. Present preliminary research findings at a meeting
or conference, and after the event consider making your figures available through Figshare (http://
figshare.com) and your presentation materials
available in your institutional repository or on a

12.

13.

14.

15.

16.

17.

18.

19.

slide-sharing site such as SlideShare (www.slideshare.net) so that others may discover and share
your knowledge.
Consider communicating information about your
research via Twitter (https://twitter.com). Twitter
provides an efficient platform for communicating
and consuming science. For some practical guidance on getting started and some background, see
Twitter 101: How should I get started using Twitter?
(6). To get a better idea of how and why scientists
and physicians are using Twitter, you might find
What is Twitter and Why Scientists Need to Use It
(7), How Could Twitter Influence Science (and Why
Scientists Are on Board) (8), and Physicians on Twitter (9) of interest, as well.
Research is not just text and figures. Create a
podcast describing the research project, and submit it to YouTube (http://www.youtube.com)
or Vimeo (http://vimeo.com). The Washington
University YouTube channel offers good examples (http://www.youtube.com/user/wustlpa#p/c/
F4A14AEE489425B0). Another option for distributing podcasts is BioMed Central (http://www.
biomedcentral.com), an organization that recognizes video as an increasingly important way for
researchers to communicate their results and that
welcomes podcast submissions. Links to these podcasts are located on the BioMed Central YouTube
channel.
Issue press releases for significant findings, and
partner with your organization’s media office to
deliver findings to local media outlets.
If there is a website for the study, provide information tailored for consumers. According to the 2009
Pew Internet & American Life Project report (10),
61 percent of Americans use the Internet for health
information.
Conduct outreach visits and/or provide seminars
to other institutions, scientists, practicing physicians, and health care providers to discuss your research project.
Consider discussing the results of your research
with policy makers and other governing bodies
that issue policies, guidelines, and standards. See
Feeding your Research into the Policy Debate (11) for
a review of the pros and cons of doing this.
Keep your profile data up to date on social networking sites aimed at scientists, researchers, and/
or physicians. Inquire about these tools within your
organization. Some highly adopted institutionwide platforms include VIVO (http://vivoweb.org)
and Profiles (http://profiles.catalyst.harvard.edu).
These institutional efforts leverage structured data
about researchers to provide current and validated
information that can be used to visualize research
efforts and identify new collaborators.
Sign up for other social networking sites to increase your visibility and connect with colleagues.
Some useful sites are ResearcherID (http://www.
researcherid.com) and LinkedIn (http://www.
linkedin.com). Sites such as Nature Network

(http://network.nature.com) allow and encourage
interaction between users. Social network tools
provide a forum for disseminating your research,
promoting discussion of your work, sharing scientific information, and forming new partnerships.
20. Alternative metrics allow users to understand how
their work is being used in the online world via
bookmarks and links to the article or data, conversations on Twitter, in blogs about the work, and in
the various methods of sharing and storing content. Some great sites for viewing these “altmetrics” include Total-Impact, ReaderMeter (http://
readermeter.org), and resources at Altmetric,
including an explorer and a bookmarklet that is
easily incorporated into your Web browser bookmark bar.
References
1. National Library of Medicine. Fact Sheet: Authorship in MEDLINE. http://www.nlm.nih.gov/pubs/
factsheets/authorship.html.
2. Wiley-Blackwell. Optimizing your article for
search engines. http://authorservices.wiley.com/
bauthor/seo.asp.
3. Park DC. Publishing in the psychological sciences:
enhancing journal impact while decreasing author
fatigue. Perspect Psychol Sci 2009; 4:36–37.
4. The Open Citation Project. The effect of open access and downloads (‘hits’) on citation impact: a
bibliography of studies. http://opcit.eprints.org/
oacitation-biblio.html.
5. Piwowar HA, Day RS, Fridsma DB. Sharing detailed research data is associated with increased citation rate. PLoS ONE 2007; 2:e308. doi:10.1371/
journal.pone.0000308
6. Twitter. Twitter 101: How should I get started using
Twitter? https://support.twitter.com/groups/31twitter-basics/topics/104-welcome-to-twittersupport/articles/215585-twitter-101-how-shouldi-get-started-using-twitter#.
7. McClain C. What is Twitter and why scientists
need to use it. http://deepseanews.com/2010/08/
what-is-twitter-and-why-scientists-need-to-use-it/.
8. Shaughnessy H. How could Twitter influence science (and why scientists are on board). http://www.
forbes.com/sites/haydnshaughnessy/2012/01/15/
how-could-twitter-influence-science-and-whyscientists-are-on-board/.
9. Chretien KC, Azar J, Kind T. Physicians on Twitter.
JAMA 2011; 305:566–568.
10. Fox S, Jones S. The social life of health information.
Pew Internet & American Life Project. http://www.
pewinternet.org/Reports/2009/8-The-Social-Lifeof-Health-Information.aspx.
11. Pain E. Feeding your research into the policy
debate.http://sciencecareers.sciencemag.org/career_
magazine/previous_issues/articles/2010_07_30/
caredit.a1000074.
Adapted from the Becker Medical Library Model for Assessment of Research Impact, available at https://becker.
wustl.edu/impact-assessment/strategies.
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In Advanced Renal Cell Carcinoma...

INDICATION
VOTRIENT is indicated for the treatment of patients
with advanced renal cell carcinoma (RCC).

IMPORTANT SAFETY INFORMATION
WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been
observed in clinical studies. Monitor hepatic
function and interrupt, reduce, or discontinue
dosing as recommended. See “Warnings and
Precautions,” Section 5.1, in complete Prescribing
Information.
• Hepatic Effects: Patients with pre-existing hepatic
impairment should use VOTRIENT with caution.
In patients with pre-existing moderate hepatic
impairment, the starting dose of VOTRIENT should
be reduced to 200 mg per day or alternatives to
VOTRIENT should be considered. Treatment with
VOTRIENT is not recommended in patients with severe
hepatic impairment. Increases in serum transaminase
levels (ALT, AST) and bilirubin were observed. Severe
and fatal hepatotoxicity has occurred. Transaminase
elevations occur early in the course of treatment
(92.5% of all transaminase elevations of any grade
occurred in the first 18 weeks). Concomitant use of

VOTRIENT and simvastatin increases the risk of
ALT elevations and should be undertaken with
caution [see Drug Interactions]. Before the initiation
of treatment and regularly during treatment, monitor
hepatic function and interrupt, reduce, or
discontinue dosing as recommended.
• QT Prolongation and Torsades de Pointes:
Prolonged QT intervals and arrhythmias, including
torsades de pointes, have been observed with
VOTRIENT. Use with caution in patients at higher
risk of developing QT interval prolongation, in
patients taking antiarrhythmics or other medications
that may prolong QT interval, and those with
relevant pre-existing cardiac disease. Baseline
and periodic monitoring of electrocardiograms
and maintenance of electrolytes within the normal
range should be performed.
• Hemorrhagic Events: Fatal hemorrhagic events have
been reported (all Grades [16%] and Grades 3 to 5
[2%]). VOTRIENT has not been studied in patients
who have a history of hemoptysis, cerebral, or clinically
significant gastrointestinal hemorrhage in the past
6 months and should not be used in those patients.
• Arterial Thrombotic Events: Arterial thrombotic
events have been observed and can be fatal. In clinical
RCC studies of VOTRIENT, myocardial infarction,
angina, ischemic stroke, and transient ischemic attack
(all Grades [3%] and Grades 3 to 5 [2%]) were

observed. Use with caution in patients who are at
increased risk for these events.
• Gastrointestinal Perforation and Fistula:
Gastrointestinal perforation or fistula has occurred.
Fatal perforation events have occurred. Use with
caution in patients at risk for gastrointestinal
perforation or fistula. Monitor for symptoms of
gastrointestinal perforation or fistula.
• Hypertension: Hypertension, including hypertensive
crisis, has been observed. Blood pressure should be
well-controlled prior to initiating VOTRIENT. Monitor
for hypertension and treat as needed. Hypertension
was observed in 47% of patients with RCC treated
with VOTRIENT. Hypertension occurs early in the
course of treatment (39% of cases occurred by Day
9 and 88% of cases occurred in the first 18 weeks).
In the case of persistent hypertension despite antihypertensive therapy, the dose of VOTRIENT may be
reduced. VOTRIENT should be discontinued if there
is evidence of hypertensive crisis or if hypertension is
severe and persistent despite anti-hypertensive therapy
and dose reduction of VOTRIENT.
• Wound Healing: VOTRIENT may impair wound
healing. Temporary interruption of therapy with
VOTRIENT is recommended in patients undergoing
surgical procedures. VOTRIENT should be
discontinued in patients with wound dehiscence.
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Move Forward With VOTRIENT
In a phase 3, randomized, double-blind, placebo-controlled trial, VOTRIENT provided significant improvement
in progression-free survival (PFS) in both treatment-naïve and cytokine-pretreated patients with advanced RCC1,2

All patients

Treatment-naïve patients

Cytokine-pretreated patients

11.1 months
(95% CI, 7.4-14.8)

7.4 months
(95% CI, 5.6-12.9)

overall median PFS with VOTRIENT (n=290)
vs 4.2 months (95% CI, 2.8-4.2)
with placebo (n=145) (P<0.001) 1,3

median PFS with VOTRIENT (n=155)
vs 2.8 months (95% CI, 1.9-5.6)
with placebo (n=78) (P<0.001) 1,3

median PFS with VOTRIENT (n=135)
vs 4.2 months (95% CI, 2.8-5.6)
with placebo (n=67) (P<0.001) 1.3

9.2 months
(95% CI, 7.4-12.9)

NCCN Guidelines® Category 1 recommendation4
• As a first-line therapy for relapsed or Stage IV unresectable RCC of predominant clear cell histology. These Guidelines also include
therapies other than VOTRIENT as first-line treatment options

WARNING: HEPATOTOXICITY

Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor hepatic function
and interrupt, reduce, or discontinue dosing as recommended. See “Warnings and Precautions,”
Section 5.1, in complete Prescribing Information.
VOTRIENT: Safety Profile Summary1
• Most common adverse events observed with VOTRIENT were diarrhea, hypertension, hair color changes
(depigmentation), nausea, anorexia, and vomiting
— Grade 3/4 fatigue occurred in 2% of patients; all grades, 19% of patients
— Grade 3/4 asthenia occurred in 3% of patients; all grades, 14% of patients
• For any individual adverse reaction in the VOTRIENT arm, the rate of Grade 3/4 adverse events is ≤4%

Most common laboratory abnormalities were ALT and AST increases1
• Grade 3 ALT increases occurred in 10% of patients; grade 4, 2% of patients;
all grades, 53% of patients
• In clinical trials, 92.5% of all transaminase elevations of any grade occurred
in the first 18 weeks of treatment with VOTRIENT
• Monitor serum liver tests before initiation of treatment with VOTRIENT and at least
once every 4 weeks for at least the first 4 months of treatment or as clinically indicated.
Periodic monitoring should then continue after this time period

• Hypothyroidism: Hypothyroidism was reported as an
adverse reaction in 26/586 (4%). Monitoring of thyroid
function tests is recommended.
• Proteinuria: Monitor urine protein. Proteinuria was
reported in 44/586 (8%) (Grade 3, 5/586 [<1%] and
Grade 4, 1/586 [<1%]). Baseline and periodic urinalysis
during treatment is recommended. Discontinue for
Grade 4 proteinuria.
• Pregnancy Category D: VOTRIENT can cause fetal
harm when administered to a pregnant woman.
Women of childbearing potential should be advised of
the potential hazard to the fetus and to avoid becoming
pregnant while taking VOTRIENT.
• Drug Interactions: CYP3A4 Inhibitors (eg,
ketoconazole, ritonavir, clarithromycin): Avoid use of
strong inhibitors. Consider dose reduction of VOTRIENT
when administered with strong CYP3A4 inhibitors.
CYP3A4 Inducers (such as rifampin): Consider an
alternate concomitant medication with no or minimal
enzyme induction potential or avoid VOTRIENT.
CYP Substrates: Concomitant use of VOTRIENT with
agents with narrow therapeutic windows that are
metabolized by CYP3A4, CYP2D6, or CYP2C8 is
not recommended.
Concomitant use of VOTRIENT and simvastatin
increases the incidence of ALT elevations. If a patient

develops ALT elevations, follow dosing guidelines
for VOTRIENT, consider alternatives to VOTRIENT or
discontinuing simvastatin. There are insufficient data
to assess the risk of concomitant administration of
alternative statins and VOTRIENT.
• Adverse Reactions: The most common adverse
reactions (>20%) for VOTRIENT versus placebo were
diarrhea (52% vs 9%), hypertension (40% vs 10%),
hair color changes (depigmentation) (38% vs 3%),
nausea (26% vs 9%), anorexia (22% vs 10%), and
vomiting (21% vs 8%).
Laboratory abnormalities occurring in >10% of patients
and more commonly (≥5%) in the VOTRIENT arm
versus placebo included increases in ALT (53% vs 22%),
AST (53% vs 19%), glucose (41% vs 33%), and total
bilirubin (36% vs 10%); decreases in phosphorus (34%
vs 11%), sodium (31% vs 24%), magnesium (26% vs
14%), and glucose (17% vs 3%); and leukopenia (37%
vs 6%), neutropenia (34% vs 6%), thrombocytopenia
(32% vs 5%), and lymphocytopenia (31% vs 24%).
VOTRIENT has been associated with cardiac
dysfunction (such as a decrease in ejection fraction
and congestive heart failure) in patients with various
cancer types, including RCC. In the overall safety
population for RCC (N=586), cardiac dysfunction
was observed in 4/586 patients (<1%).

Please see Brief Summary of Prescribing
Information on adjacent pages.
References: 1. VOTRIENT® (pazopanib) Tablets [package insert].
Research Triangle Park, NC: GlaxoSmithKline; 2012. 2. Sternberg
CN, et al. J Clin Oncol. 2010;28(6):1061-1068. 3. Data on file,
GlaxoSmithKline. 4. Referenced with permission from The NCCN
Clinical Practice Guidelines in Oncology® for Kidney Cancer V.2.2012.
©National Comprehensive Cancer Network, Inc 2012. All rights
reserved. Accessed March 22, 2012. To view the most recent and
complete version of the guideline, go online to www.nccn.org.
NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN
GUIDELINES®, and all other NCCN content are trademarks owned by
the National Comprehensive Cancer Network, Inc.
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Journal View
Would you trade life
expectancy to avoid
dialysis?
Many patients approaching end stage renal disease (ESRD) are willing to accept
significant reductions in survival to avoid
some of the burdens and limitations associated with dialysis, suggests a study in the
Canadian Medical Association Journal.
The researchers performed a “discrete
choice” experiment including 105 adult
patients with stage 3 to 5 kidney disease at
Australian renal clinics. The study looked
at how various treatment characteristics affected patients’ preferences for dialysis versus conservative care for progressive kidney
disease. Variables included life expectancy,
number of visits to the hospital per week,
ability to travel, time spent undergoing dialysis, and other factors.
Patients were more likely to opt for
dialysis if it increased their average life
expectancy: odds ratio (OR) 1.84. Other
factors affecting the preference for dialysis
were the availability of dialysis during the
evening as well as during daytime hours,
OR 8.95; and the availability of subsidized
transportation, OR 1.55. By contrast, patients were less likely to choose dialysis if it
involved more hospital visits, OR 0.70; or
if it placed more limits on their ability to
travel, OR 0.47.
Patients would accept a 7-month reduction in life expectancy to avoid one extra
hospital visit per week, and a 15-month reduction to decrease their travel restrictions.
Patient age was not a significant influencing factor.
The results suggest that, even if dialysis means longer survival, many patients
with ESRD would prefer conservative care
under certain circumstances. Patients are
“willing to trade considerable life expectancy to reduce the burdens and restrictions
of dialysis,” the researchers write. They call
for further study of decision making in
older patients with ESRD, and of patient
preferences regarding the type and location
of dialysis [Morton RL, et al. Factors influencing patient choice of dialysis versus conservative care to treated end-stage kidney
disease. CMAJ 2012; 184:E277–E283].

Mesenchymal stem cells
as induction therapy for
kidney transplant
For living-related donor kidney recipients,
induction therapy with autologous mesenchymal stem cells (MSCs) can improve
transplant outcomes, reports a study in the
Journal of the American Medical Association.
The trial included 159 patients who
were scheduled for living-related donor
kidney transplantation from an ABOcompatible, cross match–negative donor.
In a 2:1 ratio, patients were randomly
assigned to induction therapy with marrow-derived autologous MSCs or anti–
interleukin-2 antibody (basiliximab).
Autologous MSCs were given at a con-

centration of 1 to 2 x 106/kg at the time
of kidney reperfusion, repeated at 2 weeks.
All patients also received calcineurin inhibitors (CNIs); one-half of the MSC
group received CNIs at 80 percent of the
standard dose.
At 13 and 30 months, there were no
significant differences in patient or graft
survival. The 6-month rates of biopsyconfirmed graft rejection were lower in
patients receiving autologous MSCs: 7.5
percent with standard-dose CNI and 7.7

percent with low-dose CNI, compared
with 21.6 percent in the basiliximab group.
Induction therapy with MSCs also led to
faster recovery of renal function during the
first month after transplant in comparison
with control individuals: mean difference
6.2–10.0 mL/min per 1.73 m2. At 1 year,
patients in the MSC groups had a significantly lower rate of opportunistic infections: hazard ratio 0.42.
Autologous MSCs are a possible alternative to induction therapy with anti–in-

BRIEF SUMMARY
VOTRIENT (pazopanib) tablets
The following is a brief summary only; see full prescribing information for
complete product information.
WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies.
Monitor hepatic function and interrupt, reduce, or discontinue dosing
as recommended. [See Warnings and Precautions (5.1).]
1 INDICATIONS AND USAGE
VOTRIENT® is indicated for the treatment of patients with advanced renal cell
carcinoma (RCC).
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosing: The recommended dose of VOTRIENT is
800 mg orally once daily without food (at least 1 hour before or 2 hours after
a meal) [see Clinical Pharmacology (12.3) of full prescribing information]. The
dose of VOTRIENT should not exceed 800 mg. Do not crush tablets due to the
potential for increased rate of absorption which may affect systemic exposure.
[See Clinical Pharmacology (12.3) of full prescribing information.] If a dose is
missed, it should not be taken if it is less than 12 hours until the next dose.
2.2 Dose Modification Guidelines: Initial dose reduction should be 400 mg,
and additional dose decrease or increase should be in 200 mg steps based on
individual tolerability. The dose of VOTRIENT should not exceed 800 mg.
Hepatic Impairment: No dose adjustment is required in patients with mild
hepatic impairment. In patients with moderate hepatic impairment, alternatives
to VOTRIENT should be considered. If VOTRIENT is used in patients with
moderate hepatic impairment, the dose should be reduced to 200 mg per day.
VOTRIENT is not recommended in patients with severe hepatic impairment.
[See Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) of
full prescribing information.] Concomitant Strong CYP3A4 Inhibitors: The
concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir,
clarithromycin) may increase pazopanib concentrations and should be avoided.
If coadministration of a strong CYP3A4 inhibitor is warranted, reduce the dose
of VOTRIENT to 400 mg. Further dose reductions may be needed if adverse
effects occur during therapy. This dose is predicted to adjust the pazopanib
AUC to the range observed without inhibitors. However, there are no clinical
data with this dose adjustment in patients receiving strong CYP3A4 inhibitors.
[See Drug Interactions (7.1).] Concomitant Strong CYP3A4 Inducer: The
concomitant use of strong CYP3A4 inducers (e.g., rifampin) may decrease
pazopanib concentrations and should be avoided. VOTRIENT should not be
used in patients who can not avoid chronic use of strong CYP3A4 inducers.
[See Drug Interactions (7.1).]
4 CONTRAINDICATIONS
None.
5 WARNINGS AND PRECAUTIONS
5.1 Hepatic Effects: In clinical trials with VOTRIENT, hepatotoxicity, manifested
as increases in serum transaminases (ALT, AST) and bilirubin, was observed
[see Adverse Reactions (6.1)]. This hepatotoxicity can be severe and fatal.
Transaminase elevations occur early in the course of treatment (92.5% of all
transaminase elevations of any grade occurred in the first 18 weeks). Across all
monotherapy studies with VOTRIENT, ALT >3 X upper limit of normal (ULN) was
reported in 138/977 (14%) and ALT >8 X ULN was reported in 40/977 (4%) of
patients who received VOTRIENT. Concurrent elevations in ALT >3 X ULN and
bilirubin >2 X ULN regardless of alkaline phosphatase levels were detected in
13/977 (1%) of patients. Four of the 13 patients had no other explanation for these
elevations. Two of 977 (0.2%) patients died with disease progression and hepatic
failure. Monitor serum liver tests before initiation of treatment with VOTRIENT
and at least once every 4 weeks for at least the first 4 months of treatment or as
clinically indicated. Periodic monitoring should then continue after this time
period. Patients with isolated ALT elevations between 3 X ULN and 8 X ULN may
be continued on VOTRIENT with weekly monitoring of liver function until ALT
return to Grade 1 or baseline. Patients with isolated ALT elevations of >8 X ULN
should have VOTRIENT interrupted until they return to Grade 1 or baseline. If the
potential benefit for reinitiating treatment with VOTRIENT is considered to
outweigh the risk for hepatotoxicity, then reintroduce VOTRIENT at a reduced
dose of no more than 400 mg once daily and measure serum liver tests weekly
for 8 weeks [see Dosage and Administration (2.2)]. Following reintroduction of
VOTRIENT, if ALT elevations >3 X ULN recur, then VOTRIENT should be
permanently discontinued. If ALT elevations >3 X ULN occur concurrently with
bilirubin elevations >2 X ULN, VOTRIENT should be permanently discontinued.
Patients should be monitored until resolution. VOTRIENT is a UGT1A1 inhibitor.
Mild, indirect (unconjugated) hyperbilirubinemia may occur in patients with
Gilbert’s syndrome [see Clinical Pharmacology (12.5) of full prescribing
information]. Patients with only a mild indirect hyperbilirubinemia, known
Gilbert’s syndrome, and elevation in ALT >3 X ULN should be managed as per
the recommendations outlined for isolated ALT elevations. Concomitant use of
VOTRIENT and simvastatin increases the risk of ALT elevations and should be
undertaken with caution and close monitoring [see Drug Interactions (7.3)].
Insufficient data are available to assess the risk of concomitant administration
of alternative statins and VOTRIENT. In patients with pre-existing moderate

terleukin-2 antibody, with the potential
to lower rejection risk. This open-label
trial finds several advantages of MSC induction therapy, including a lower acute
rejection rate, more rapid return of kidney function, and a lower rate of opportunistic infections. Long-term follow-up
studies are planned [Tan J, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney
transplants: a randomized controlled
trial. JAMA 2012; 307:1169–1177].

hepatic impairment, the starting dose of VOTRIENT should be reduced or
alternatives to VOTRIENT should be considered. Treatment with VOTRIENT is not
recommended in patients with pre-existing severe hepatic impairment, defined
as total bilirubin >3 X ULN with any level of ALT. [See Dosage and Administration
(2.2), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) of full
prescribing information.] 5.2 QT Prolongation and Torsades de Pointes: In
clinical RCC studies of VOTRIENT, QT prolongation (≥500 msec) was identified
on routine electrocardiogram monitoring in 11/558 (<2%) of patients. Torsades
de pointes occurred in 2/977 (<1%) of patients who received VOTRIENT in the
monotherapy studies. In the randomized clinical trial, 3 of the 290 patients
receiving VOTRIENT had post-baseline values between 500 to 549 msec. None
of the 145 patients receiving placebo had post-baseline QTc values ≥500 msec.
VOTRIENT should be used with caution in patients with a history of QT interval
prolongation, in patients taking antiarrhythmics or other medications that may
prolong QT interval, and those with relevant pre-existing cardiac disease. When
using VOTRIENT, baseline and periodic monitoring of electrocardiograms and
maintenance of electrolytes (e.g., calcium, magnesium, potassium) within the
normal range should be performed. 5.3 Hemorrhagic Events: In clinical RCC
studies of VOTRIENT, hemorrhagic events have been reported [all Grades (16%)
and Grades 3 to 5 (2%)]. Fatal hemorrhage has occurred in 5/586 (0.9%)
[see Adverse Reactions (6.1)]. VOTRIENT has not been studied in patients who
have a history of hemoptysis, cerebral, or clinically significant gastrointestinal
hemorrhage in the past 6 months and should not be used in those patients.
5.4 Arterial Thrombotic Events: In clinical RCC studies of VOTRIENT,
myocardial infarction, angina, ischemic stroke, and transient ischemic attack
[all Grades (3%) and Grades 3 to 5 (2%)] were observed. Fatal events have been
observed in 2/586 (0.3%). In the randomized study, these events were observed
more frequently with VOTRIENT compared to placebo [see Adverse Reactions
(6.1)]. VOTRIENT should be used with caution in patients who are at increased
risk for these events or who have had a history of these events. VOTRIENT has
not been studied in patients who have had an event within the previous 6
months and should not be used in those patients. 5.5 Gastrointestinal
Perforation and Fistula: In clinical RCC studies of VOTRIENT, gastrointestinal
perforation or fistula has been reported in 5 patients (0.9%). Fatal perforation
events have occurred in 2/586 (0.3%). Monitor for symptoms of gastrointestinal
perforation or fistula. 5.6 Hypertension : In clinical studies, events of
hypertension including hypertensive crisis have occurred. Blood pressure
should be well-controlled prior to initiating VOTRIENT. Patients should be
monitored for hypertension and treated as needed with anti-hypertensive
therapy. Hypertension (systolic blood pressure ≥150 or diastolic blood pressure
≥100 mm Hg) was observed in 47% of patients with RCC treated with
VOTRIENT. Hypertension occurs early in the course of treatment (39% of
cases occurred by Day 9 and 88% of cases occurred in the first 18 weeks).
[See Adverse Reactions (6.1).] In the case of persistent hypertension despite
anti-hypertensive therapy, the dose of VOTRIENT may be reduced [see Dosage
and Administration (2.2)]. VOTRIENT should be discontinued if there is evidence
of hypertensive crisis or if hypertension is severe and persistent despite
anti-hypertensive therapy and dose reduction of VOTRIENT. 5.7 Wound
Healing: No formal studies on the effect of VOTRIENT on wound healing have
been conducted. Since vascular endothelial growth factor receptor (VEGFR)
inhibitors such as pazopanib may impair wound healing, treatment with
VOTRIENT should be stopped at least 7 days prior to scheduled surgery.
The decision to resume VOTRIENT after surgery should be based on clinical
judgment of adequate wound healing. VOTRIENT should be discontinued in
patients with wound dehiscence. 5.8 Hypothyroidism: In clinical RCC studies
of VOTRIENT, hypothyroidism reported as an adverse reaction in 26/586 (4%)
[see Adverse Reactions (6.1)]. Proactive monitoring of thyroid function tests is
recommended. 5.9 Proteinuria: In clinical RCC studies with VOTRIENT,
proteinuria has been reported in 44/586 (8%) [Grade 3, 5/586 (<1%) and Grade
4, 1/586 (<1%)] [see Adverse Reactions (6.1)]. Baseline and periodic urinalysis
during treatment is recommended. VOTRIENT should be discontinued if the
patient develops Grade 4 proteinuria. 5.10 Pregnancy: VOTRIENT can cause
fetal harm when administered to a pregnant woman. Based on its mechanism
of action, VOTRIENT is expected to result in adverse reproductive effects. In
pre-clinical studies in rats and rabbits, pazopanib was teratogenic, embryotoxic,
fetotoxic, and abortifacient. There are no adequate and well-controlled studies
of VOTRIENT in pregnant women. If this drug is used during pregnancy, or if the
patient becomes pregnant while taking this drug, the patient should be apprised
of the potential hazard to the fetus. Women of childbearing potential should be
advised to avoid becoming pregnant while taking VOTRIENT. [See Use in
Specific Populations (8.1).]
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience: Because clinical trials are conducted under
widely varying conditions, adverse reaction rates observed in the clinical trials
of a drug cannot be directly compared to rates in the clinical trials of another
drug and may not reflect the rates observed in practice. Potentially serious
adverse reactions with VOTRIENT included hepatotoxicity, QT prolongation
and torsades de pointes, hemorrhagic events, arterial thrombotic events,
gastrointestinal perforation and fistula, and hypertensive crisis [see Warnings
and Precautions (5.1-5.5)]. The safety of VOTRIENT has been evaluated in 977
patients in the monotherapy studies which included 586 patients with RCC
at the time of NDA submission. With a median duration of treatment of 7.4
months (range 0.1 to 27.6), the most commonly observed adverse reactions
(≥20%) in the 586 patients were diarrhea, hypertension, hair color change,
nausea, fatigue, anorexia, and vomiting. The data described below reflect
the safety profile of VOTRIENT in 290 RCC patients who participated in a
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Ten percent rate of chronic kidney disease in children with acute kidney injury
At least 10 percent of children with acute
kidney injury (AKI) in a children’s hospital
intensive care unit (ICU) will experience
chronic kidney disease (CKD) within the
next few years, according to a report in the
American Journal of Kidney Disease.
The researchers analyzed prospective
follow-up data on 126 children with AKI
admitted to the pediatric ICU in a Canadian children’s hospital from 2006 to 2008.

(Another 173 children were lost to followup.) One-fourth of the patients were newborns; in more than half, AKI was associated with open-heart surgery.
As defined by AKI Network criteria,
severity was stage 1 in 35 percent of children, stage 2 in 37 percent, and stage 3 in
28 percent. At 1–3 years of follow-up, the
rates of CKD—defined as the presence of
albuminuria and/or glomerular filtration

randomized, double-blind, placebo-controlled study [see Clinical Studies (14) of
full prescribing information]. The median duration of treatment was 7.4 months
(range 0 to 23) for patients who received VOTRIENT and 3.8 months (range 0
to 22) for the placebo arm. Forty-two percent (42%) of patients on VOTRIENT
required a dose interruption. Thirty-six percent (36%) of patients on VOTRIENT
were dose reduced. Table 1 presents the most common adverse reactions
occurring in ≥10% of patients who received VOTRIENT.
Table 1. Adverse Reactions Occurring in ≥10% of Patients who Received
VOTRIENT
VOTRIENT

Placebo

(N = 290)

(N = 145)

All
All
Gradesa Grade 3 Grade 4 Gradesa Grade 3 Grade 4
Adverse Reactions
Diarrhea
Hypertension
Hair color changes
Nausea
Anorexia
Vomiting
Fatigue
Asthenia
Abdominal pain
Headache
a

%

%

%

%

%

%

52
40
38
26
22
21
19
14
11
10

3
4
<1
<1
2
2
2
3
2
0

<1
0
0
0
0
<1
0
0
0
0

9
10
3
9
10
8
8
8
1
5

<1
<1
0
0
<1
2
1
0
0
0

0
0
0
0
0
0
1
0
0
0

National Cancer Institute Common Terminology Criteria for Adverse Events,
version 3.

Other adverse reactions observed more commonly in patients treated with
VOTRIENT than placebo and that occurred in <10% (any grade) were alopecia
(8% versus <1%), chest pain (5% versus 1%), dysgeusia (altered taste) (8%
versus <1%), dyspepsia (5% versus <1%), facial edema (1% versus 0%),
palmar-plantar erythrodysesthesia (hand-foot syndrome) (6% versus <1%),
proteinuria (9% versus 0%), rash (8% versus 3%), skin depigmentation (3%
versus 0%), and weight decreased (9% versus 3%).

Parameters

Placebo
(N = 145)

All
All
Gradesa Grade 3 Grade 4 Gradesa Grade 3 Grade 4
%
%
%
%
%
%

Hematologic
Leukopenia
37
0
0
6
0
0
Neutropenia
34
1
<1
6
0
0
Thrombocytopenia
32
<1
<1
5
0
<1
Lymphocytopenia
31
4
<1
24
1
0
Chemistry
ALT increased
53
10
2
22
1
0
AST increased
53
7
<1
19
<1
0
Glucose
41
<1
0
33
1
0
increased
Total bilirubin
36
3
<1
10
1
<1
increased
Phosphorus
34
4
0
11
0
0
decreased
Sodium
31
4
1
24
4
0
decreased
Magnesium
26
<1
1
14
0
0
decreased
Glucose
17
0
<1
3
0
0
decreased
a
National Cancer Institute Common Terminology Criteria for Adverse Events,
version 3.
Hepatic Toxicity: In a controlled clinical study with VOTRIENT for the treatment
of RCC, ALT >3 X ULN was reported in 18% and 3% of the VOTRIENT and

7 DRUG INTERACTIONS
7.1 Drugs That Inhibit or Induce Cytochrome P450 3A4 Enzymes: In vitro
studies suggested that the oxidative metabolism of pazopanib in human liver
microsomes is mediated primarily by CYP3A4, with minor contributions from
CYP1A2 and CYP2C8. Therefore, inhibitors and inducers of CYP3A4 may alter
the metabolism of pazopanib. CYP3A4 Inhibitors: Coadministration of pazopanib
with strong inhibitors of CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin)
may increase pazopanib concentrations. A dose reduction for VOTRIENT should
be considered when it must be coadministered with strong CYP3A4 inhibitors
[see Dosage and Administration (2.2)]. Grapefruit juice should be avoided
as it inhibits CYP3A4 activity and may also increase plasma concentrations
of pazopanib. CYP3A4 Inducers: CYP3A4 inducers such as rifampin may
decrease plasma pazopanib concentrations. VOTRIENT should not be used if
chronic use of strong CYP3A4 inducers can not be avoided [see Dosage and
Administration (2.2)]. 7.2 Effects of Pazopanib on CYP Substrates: Results
from drug-drug interaction studies conducted in cancer patients suggest that
pazopanib is a weak inhibitor of CYP3A4, CYP2C8, and CYP2D6 in vivo, but
had no effect on CYP1A2, CYP2C9, or CYP2C19 [see Clinical Pharmacology
(12.3) of full prescribing information]. Concomitant use of VOTRIENT with
agents with narrow therapeutic windows that are metabolized by CYP3A4,
CYP2D6, or CYP2C8 is not recommended. Coadministration may result in
inhibition of the metabolism of these products and create the potential for
serious adverse events. [See Clinical Pharmacology (12.3) of full prescribing
information.] 7.3 Effect of Concomitant use of VOTRIENT and Simvastatin:
Concomitant use of VOTRIENT and simvastatin increases the incidence of ALT
elevations. Across monotherapy studies with VOTRIENT, ALT >3 X ULN was

Dipeptidyl peptidase-4 (DPP-4) inhibitors are an effective alternative for secondline therapy in patients with type 2 diabetes, reports a meta-analysis in the British
Medical Journal.
The analysis pooled data from 19 randomized trials, including 7136 patients
assigned to a DPP-4 inhibitor and 6745
to other hypoglycemic treatments. The
results showed a smaller decrease in glycated hemoglobin (HbA1c) with DPP4 inhibitors compared with metformin
alone, weighted mean difference 0.20; and
a lesser decrease in body weight, weighted
mean difference 1.50.
As second-line treatment to reduce
HbA1c, DPP-4 inhibitors were less effective than glucagon-like peptide-1 (GLP-1)
agonists and sulfonylureas but were similar
to pioglitazone. The DPP-4 inhibitors led
to more favorable changes in body weight
compared with sulfonylureas or pioglitazone but not compared with GLP-1 agonists.
Studies comparing DPP-4 inhibitors
against metformin alone or with pioglitazone or against a GLP-1 agonist included
few episodes of hypoglycemia. Most studies comparing a DPP-4 inhibitor plus a
sulfonylurea against metformin showed
a higher risk of hypoglycemia in patients
taking sulfonylureas. The DDP-4 inhibitors had a lower rate of serious adverse
events than did pioglitazone. They did not
increase the risks of nasopharyngitis, upper respiratory tract infection, or urinary
tract infection.
The updated review and meta-analysis
may help to clarify the clinical role of the
DPP-4 inhibitors, a newer class of oral
hypoglycemic drugs. These medications
appear to be effective in lowering HbA1c
in patients with type 2 diabetes who do
not respond to metformin alone. Further
study is needed to assess their cost effectiveness and long-term safety outcomes
[Karagiannis T, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2
diabetes mellitus in the clinical setting:
systematic review and meta-analysis. BMJ
2012; 344:e1369].
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VOTRIENT
(N = 290)

Clinical role of DPP4 inhibitors in type 2
diabetes
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Table 2. Selected Laboratory Abnormalities Occurring in >10% of Patients
who Received VOTRIENT and More Commonly (≥5%) in Patients who
Received VOTRIENT Versus Placebo

placebo groups, respectively. ALT >10 X ULN was reported in 4% of patients
who received VOTRIENT and in <1% of patients who received placebo.
Concurrent elevation in ALT >3 X ULN and bilirubin >2 X ULN in the absence of
significant alkaline phosphatase >3 X ULN occurred in 5/290 (2%) of patients on
VOTRIENT and 2/145 (1%) on placebo. [See Dosage and Administration (2.2) of
full prescribing information and Warnings and Precautions (5.1).] Hypertension:
In a controlled clinical study with VOTRIENT for the treatment of RCC, 115/290
patients (40%) receiving VOTRIENT compared with 15/145 patients (10%)
on placebo experienced hypertension. Grade 3 hypertension was reported in
13/290 patients (4%) receiving VOTRIENT compared with 1/145 patients (<1%)
on placebo. The majority of cases of hypertension were manageable with antihypertensive agents or dose reductions with 2/290 patients (<1%) permanently
discontinuing treatment with VOTRIENT because of hypertension. VOTRIENT
has been associated with hypertensive crisis in patients with various cancer
types including RCC. In the overall safety population for RCC (N = 586), one
patient had hypertensive crisis on VOTRIENT. [See Warnings and Precautions
(5.6).] QT Prolongation and Torsades de Pointes: In a controlled clinical
study with VOTRIENT, QT prolongation (≥500 msec) was identified on routine
electrocardiogram monitoring in 3/290 (1%) of patients treated with VOTRIENT
compared with no patients on placebo. Torsades de pointes was reported in
2/586 (<1%) patients treated with VOTRIENT in the RCC studies. [See Warnings
and Precautions (5.2).] Arterial Thrombotic Events: In a controlled clinical
study with VOTRIENT, the incidences of arterial thrombotic events such as
myocardial infarction/ischemia [5/290 (2%)], cerebral vascular accident [1/290
(<1%)], and transient ischemic attack [4/290 (1%)] were higher in patients
treated with VOTRIENT compared to the placebo arm (0/145 for each event).
[See Warnings and Precautions (5.4).] Hemorrhagic Events: In a controlled
clinical study with VOTRIENT, 37/290 patients (13%) treated with VOTRIENT
and 7/145 patients (5%) on placebo experienced at least 1 hemorrhagic event.
The most common hemorrhagic events in the patients treated with VOTRIENT
were hematuria (4%), epistaxis (2%), hemoptysis (2%), and rectal hemorrhage
(1%). Nine (9/37) patients treated with VOTRIENT who had hemorrhagic
events experienced serious events including pulmonary, gastrointestinal, and
genitourinary hemorrhage. Four (4/290) (1%) patients treated with VOTRIENT
died from hemorrhage compared with no (0/145) (0%) patients on placebo.
[See Warnings and Precautions (5.3).] In the overall safety population in RCC
(N = 586), cerebral/intracranial hemorrhage was observed in 2/586 (<1%)
patients treated with VOTRIENT. Hypothyroidism: In a controlled clinical study
with VOTRIENT, more patients had a shift from thyroid stimulating hormone
(TSH) within the normal range at baseline to above the normal range at any
post-baseline visit in VOTRIENT compared with the placebo arm (27% compared
with 5%, respectively). Hypothyroidism was reported as an adverse reaction in
19 patients (7%) treated with VOTRIENT and no patients (0%) in the placebo arm.
[See Warnings and Precautions (5.8).] Diarrhea: Diarrhea occurred frequently
and was predominantly mild to moderate in severity. Patients should be advised
how to manage mild diarrhea and to notify their healthcare provider if moderate
to severe diarrhea occurs so appropriate management can be implemented to
minimize its impact. Proteinuria: In the controlled clinical study with VOTRIENT,
proteinuria has been reported as an adverse reaction in 27 patients (9%) treated
with VOTRIENT. In 2 patients, proteinuria led to discontinuation of treatment with
VOTRIENT. [See Warnings and Precautions (5.9).] Lipase Elevations: In a singlearm clinical study, increases in lipase values were observed for 48/181 patients
(27%). Elevations in lipase as an adverse reaction were reported for 10 patients
(4%) and were Grade 3 for 6 patients and Grade 4 for 1 patient. In clinical RCC
studies of VOTRIENT, clinical pancreatitis was observed in 4/586 patients (<1%).
Cardiac Dysfunction: Pazopanib has been associated with cardiac dysfunction
(such as a decrease in ejection fraction and congestive heart failure) in patients
with various cancer types, including RCC. In the overall safety population for RCC
(N = 586), cardiac dysfunction was observed in 4/586 patients (<1%).

blood pressure, or hyperfiltration (GFR
60–90 mL/min/1.73 m2).
Of these tertiary care pediatric
ICU patients with AKI, more than 10 percent go on to experience CKD. Overall,
most of these children either have CKD
or are considered at risk for the development of CKD at follow-up. The authors
believe that all children with AKI should
receive regular monitoring for possible kidney damage [Mammen C, et al. Long-term
risk of CKD in children surviving episodes
of acute kidney injury in the intensive care
unit: a prospective cohort study. Am J Kidney Dis 2012; 59:523–530].
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Table 2 presents the most common laboratory abnormalities occurring in >10%
of patients who received VOTRIENT and more commonly (≥5%) in patients who
received VOTRIENT versus placebo.

rate (GFR) less than 60 mL/min/1.73
m2—was assessed.
At follow-up, the criteria for CKD were
met in 10.3 percent of children who had
stage 1 AKI, 10.6 percent with stage 2
AKI, and 17.1 percent with stage 3 AKI.
Another 46.8 percent of children were
considered at risk of CKD on the basis of
mildly to moderately reduced kidney function (GFR 60–90 mL/min/1.73 m2), high
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Industry Spotlight
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New Medicare Code for Anemia Medication

I

n March 2012, Affymax and
Takeda Pharmaceuticals obtained U.S. Food and Drug Administration approval for Omontys
(peginesatide) injection, a once-amonth treatment for anemia in patients with chronic kidney disease

(CKD) who are on dialysis.
By mid-April, the Centers for
Medicare & Medicaid Services (CMS)
singled out the medication for a temporary Q-code for federal reimbursement, according to Affymax. CMS
deemed the product important for all

reported in 126/895 (14%) of patients who did not use statins, compared with
11/41 (27%) of patients who had concomitant use of simvastatin. If a patient
receiving concomitant simvastatin develops ALT elevations, follow dosing
guidelines for VOTRIENT or consider alternatives to VOTRIENT [see Warnings
and Precautions (5.1)]. Alternatively, consider discontinuing simvastatin [see
Warnings and Precautions (5.1)]. Insufficient data are available to assess the risk
of concomitant administration of alternative statins and VOTRIENT.

10 OVERDOSAGE
Pazopanib doses up to 2,000 mg have been evaluated in clinical trials.
Dose-limiting toxicity (Grade 3 fatigue) and Grade 3 hypertension were each
observed in 1 of 3 patients dosed at 2,000 mg daily and 1,000 mg daily,
respectively. Treatment of overdose with VOTRIENT should consist of general
supportive measures. There is no specific antidote for overdosage of VOTRIENT.
Hemodialysis is not expected to enhance the elimination of VOTRIENT
because pazopanib is not significantly renally excreted and is highly bound
to plasma proteins.

17 PATIENT COUNSELING INFORMATION
See Medication Guide. The Medication Guide is contained in a separate leaflet
that accompanies the product. However, inform patients of the following:
• Therapy with VOTRIENT may result in hepatobiliary laboratory abnormalities.
Monitor serum liver tests (ALT, AST, and bilirubin) prior to initiation of
VOTRIENT and at least once every 4 weeks for the first 4 months of treatment
or as clinically indicated. Inform patients that they should report any of the
following signs and symptoms of liver problems to their healthcare provider
right away.
—yellowing of the skin or the whites of the eyes (jaundice),
—unusual darkening of the urine,
—unusual tiredness,
—right upper stomach area pain.
• Gastrointestinal adverse reactions such as diarrhea, nausea, and vomiting
have been reported with VOTRIENT. Patients should be advised how to
manage diarrhea and to notify their healthcare provider if moderate to severe
diarrhea occurs.
• Women of childbearing potential should be advised of the potential hazard to
the fetus and to avoid becoming pregnant.
• Patients should be advised to inform their healthcare providers of all
concomitant medications, vitamins, or dietary and herbal supplements.
• Patients should be advised that depigmentation of the hair or skin may occur
during treatment with VOTRIENT.
• Patients should be advised to take VOTRIENT without food (at least 1 hour
before or 2 hours after a meal).
VOTRIENT is a registered trademark of GlaxoSmithKline.
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claims in a standardized manner and
reduce the turnaround time for payment. “The designation of this Qcode by CMS will help simplify their
billing process for reimbursement
when using this new once-monthly
anemia treatment for CKD patients
on dialysis,” said John Orwin, chief
executive officer of Affymax. “The
ability of dialysis centers to receive
timely reimbursement for Omontys
is important.”
According to CMS, the Q-code is
used by CMS contractors when the
existing, permanent national codes
do not have an exact code for a product or service covered by Medicare.
By the end of the first quarter of
2012 there were more than 200 Qcodes in effect for all types of medical services.
The unique aspects of dialysis
make its related treatments a fertile
ground for Q-codes. Beginning January 1, 2010, Feraheme (ferumoxytol), a different anemia medication,
received two Q-codes for its use in
patients—one code for patients with
CKD, and the other code for patients
with end stage renal disease.
The entire Medicare coding system, including the Q-codes and
other specialized codes, is called
the Healthcare Common Procedure
Coding System (HCPCS) code set.
If you have questions about HCPCS
coding or would like further information, visit http://www.cms.gov/
Medicare/Coding/MedHCPCSGenInfo/HCPCS_Coding_Questions.
html.
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13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity
studies with pazopanib have not been conducted. However, in a 13-week study
in mice, proliferative lesions in the liver including eosinophilic foci in 2 females
and a single case of adenoma in another female was observed at doses of 1,000
mg/kg/day (approximately 2.5 times the human clinical exposure based on AUC).
Pazopanib did not induce mutations in the microbial mutagenesis (Ames) assay
and was not clastogenic in both the in vitro cytogenetic assay using primary
human lymphocytes and in the in vivo rat micronucleus assay. Pazopanib may
impair fertility in humans. In female rats, reduced fertility including increased
pre-implantation loss and early resorptions were noted at dosages ≥30 mg/kg/
day (approximately 0.4 times the human clinical exposure based on AUC). Total
litter resorption was seen at 300 mg/kg/day (approximately 0.8 times the human
clinical exposure based on AUC). Post-implantation loss, embryolethality, and
decreased fetal body weight were noted in females administered doses ≥10 mg/
kg/day (approximately 0.3 times the human clinical exposure based on AUC).
Decreased corpora lutea and increased cysts were noted in mice given ≥100
mg/kg/day for 13 weeks and ovarian atrophy was noted in rats given ≥300
mg/kg/day for 26 weeks (approximately 1.3 and 0.85 times the human clinical
exposure based on AUC, respectively). Decreased corpora lutea was also noted
in monkeys given 500 mg/kg/day for up to 34 weeks (approximately 0.4 times
the human clinical exposure based on AUC). Pazopanib did not affect mating or
fertility in male rats. However, there were reductions in sperm production rates
and testicular sperm concentrations at doses ≥3 mg/kg/day, epididymal sperm
concentrations at doses ≥30 mg/kg/day, and sperm motility at ≥100 mg/kg/
day following 15 weeks of dosing. Following 15 and 26 weeks of dosing, there
were decreased testicular and epididymal weights at doses of ≥30 mg/kg/day
(approximately 0.35 times the human clinical exposure based on AUC); atrophy
and degeneration of the testes with aspermia, hypospermia and cribiform change
in the epididymis was also observed at this dose in the 6-month toxicity studies
in male rats.
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8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy: Pregnancy Category D [see Warnings and Precautions (5.10)].
VOTRIENT can cause fetal harm when administered to a pregnant woman. There
are no adequate and well-controlled studies of VOTRIENT in pregnant women. In
pre-clinical studies in rats and rabbits, pazopanib was teratogenic, embryotoxic,
fetotoxic, and abortifacient. Administration of pazopanib to pregnant rats
during organogenesis at a dose level of ≥3 mg/kg/day (approximately 0.1
times the human clinical exposure based on AUC) resulted in teratogenic
effects including cardiovascular malformations (retroesophageal subclavian
artery, missing innominate artery, changes in the aortic arch) and incomplete
or absent ossification. In addition, there was reduced fetal body weight, and
pre- and post-implantation embryolethality in rats administered pazopanib at
doses ≥3 mg/kg/day. In rabbits, maternal toxicity (reduced food consumption,
increased post-implantation loss, and abortion) was observed at doses ≥30 mg/
kg/day (approximately 0.007 times the human clinical exposure). In addition,
severe maternal body weight loss and 100% litter loss were observed at doses
≥100 mg/kg/day (0.02 times the human clinical exposure), while fetal weight
was reduced at doses ≥3 mg/kg/day (AUC not calculated). If this drug is used
during pregnancy, or if the patient becomes pregnant while taking this drug,
the patient should be apprised of the potential hazard to the fetus. Women of
childbearing potential should be advised to avoid becoming pregnant while
taking VOTRIENT. 8.3 Nursing Mothers: It is not known whether this drug
is excreted in human milk. Because many drugs are excreted in human milk
and because of the potential for serious adverse reactions in nursing infants
from VOTRIENT, a decision should be made whether to discontinue nursing
or to discontinue the drug, taking into account the importance of the drug to
the mother. 8.4 Pediatric Use: The safety and effectiveness of VOTRIENT in
pediatric patients have not been established. In repeat-dose toxicology studies
in rats including 4-week, 13-week, and 26-week administration, toxicities in
bone, teeth, and nail beds were observed at doses ≥3 mg/kg/day (approximately
0.07 times the human clinical exposure based on AUC). Doses of 300 mg/
kg/day (approximately 0.8 times the human clinical exposure based on AUC)
were not tolerated in 13- and 26-week studies with rats. Body weight loss and
morbidity were observed at these doses. Hypertrophy of epiphyseal growth
plates, nail abnormalities (including broken, overgrown, or absent nails) and
tooth abnormalities in growing incisor teeth (including excessively long, brittle,
broken and missing teeth, and dentine and enamel degeneration and thinning)
were observed in rats at ≥30 mg/kg/day (approximately 0.35 times the human
clinical exposure based on AUC) at 26 weeks, with the onset of tooth and nail
bed alterations noted clinically after 4 to 6 weeks. 8.5 Geriatric Use: In clinical
trials with VOTRIENT for the treatment of RCC, 196 subjects (33%) were
aged ≥65 years, and 34 subjects (6%) were aged >75 years. No overall
differences in safety or effectiveness of VOTRIENT were observed between
these subjects and younger subjects. However, patients >60 years of age may
be at greater risk for an ALT >3 X ULN. Other reported clinical experience has
not identified differences in responses between elderly and younger patients,
but greater sensitivity of some older individuals cannot be ruled out. 8.6 Hepatic
Impairment: In clinical studies for VOTRIENT, patients with total bilirubin ≤1.5
X ULN and AST and ALT ≤2 X ULN were included [see Warnings and Precautions
(5.1)]. An analysis of data from a pharmacokinetic study of pazopanib in patients
with varying degrees of hepatic dysfunction suggested that no dose adjustment
is required in patients with mild hepatic impairment [either total bilirubin within
normal limit (WNL) with ALT > ULN or bilirubin > 1 X to 1.5 X ULN regardless of
the ALT value]. The maximum tolerated dose in patients with moderate hepatic
impairment (total bilirubin >1.5 X to 3 X ULN regardless of the ALT value) was
200 mg per day (N = 11). The median steady-state Cmax and AUC (0-24) achieved at
this dose was approximately 40% and 29%, respectively of that seen in patients
with normal hepatic function at the recommended daily dose of 800 mg.
The maximum dose explored in patients with severe hepatic impairment
(total bilirubin > 3 X ULN regardless of the ALT value) was 200 mg per day
(N = 14). This dose was not well tolerated. Median exposures achieved at this
dose were approximately 18% and 15% of those seen in patients with normal
liver function at the recommended daily dose of 800 mg. Therefore, VOTRIENT
is not recommended in these patients [see Clinical Pharmacology (12.3) of
full prescribing information]. 8.7 Renal Impairment: Patients with renal cell
cancer and mild/moderate renal impairment (creatinine clearance ≥30 mL/
min) were included in clinical studies for VOTRIENT. There are no clinical or
pharmacokinetic data in patients with severe renal impairment or in patients
undergoing peritoneal dialysis or hemodialysis. However, renal impairment
is unlikely to significantly affect the pharmacokinetics of pazopanib since
<4% of a radiolabeled oral dose was recovered in the urine. In a population
pharmacokinetic analysis using 408 subjects with various cancers, creatinine
clearance (30-150 mL/min) did not influence clearance of pazopanib. Therefore,
renal impairment is not expected to influence pazopanib exposure, and dose
adjustment is not necessary.

dialysis centers that are treating patients who receive Medicare-covered
services. This new Q-code will go
into effect on July 1, 2012.
The new Q-code provides dialysis centers with an immediate reimbursement code so they can submit
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Medical Education Research Can Improve the Future
of Nephrology and Applies to All Types of Practice
By Laura Maursetter and Mary Thompson
Have you considered sharing
your experience in medical
education research and helping others learn about effective changes you have implemented in your program?
Consider submitting your abstract to the Medical Education Abstract category at the
ASN Kidney Week 2012.

Teaching at work

Step 2: Measure the baseline

Step 3: Plan the intervention

Sharing knowledge is a significant
part of patient care delivery as well
as trainee education. However, teaching without measuring effectiveness
does not answer whether the methods used to relay information are as
good as they can be. Taking the time
to frame a deficiency, pose an intervention, and test the results over time
can optimize best teaching practices.

A

Simulation

The measure used to determine success should be assessed before the intervention. This will validate that the
perceived deficiency is truly present,
and it will set the baseline for comparison after intervention. Determining the measure can be difficult.
Traditional teaching has suggested
quantitative findings to be the optimal assessment: “The proof is in the
numbers.” Educational research may
focus on qualitative findings as a better measure. Examples of measures
can be found in Table 2.

The intervention must be planned to
address the specific topic. Keep the
difficulty of material at the level of
the audience. Use teaching methods
that provide information in a variety
of ways to target the largest audience. Some people learn by hearing
(lectures), seeing (written word), or
doing (simulation or workshops);
therefore, it is wise to focus on interventions that address multiple means
of knowledge delivery (6–8).

n important task for all physicians is to educate. This may apply to those teaching the next generation of nephrologists, but it also
goes far beyond that task. Medical
education includes information provided to patients, colleagues, nursing
staff, dieticians, and trainees about
concepts concerning physiology or
pathophysiology. For example, teaching a patient the reason to keep phosphorus levels controlled and noting the improvement in subsequent
laboratory results is an effective educational intervention. In medical
education research, the project must
have a specific question with a measurable outcome to determine the success of the change.
Although it might seem that medical education research is meant for
academic institutions, this type of research may be performed in all practice settings. The number of investigations linking medical education and
quality of care or patient outcomes is
minimal (1). Research is needed to determine whether the changes in medical education implemented are useful
or wasted effort. An example is this
could easily apply to fellowship training, where outcomes-based education
has been implemented without strong
evidence to back this change (2). Specifically, further investigation is necessary to determine whether the type of
education given to the next generation
will create nephrologists who provide
higher-quality care with improved
patient outcomes. The following examples will highlight some potential
areas of practice where medical education research can be applied (Table 1).

Quality improvement projects
Quality improvement is a recertification requirement for all nephrologists. This project could bring many
members of a team together for collaboration on enhancing an educational aspect of practice (2). The PlanDo-Study-Act method is a model for
testing a change that is implemented
(3). The four steps guide the thinking
process and lead to an outcome that is
measured for success.

Medical simulation is a rapidly growing field, and credentialing organizations are requiring it as part of the
training curriculum. Simulation can
be used to perfect technical skills in
performing procedures but also to
assist in improving interactions with
patients. Whichever skill is being
practiced, simulation provides an opportunity for feedback to be given to
participants. Repeating these sessions
can provide a way to evaluate learning over time (4).

Table 1. Educational research areas and implementation and
analysis methods
Research Area

Implementation (Analysis Method)

Quality
Improvement
Project

• Requirement for recertification
• Audience: trainees, nurses, dieticians, dialysis
technologists, colleagues
• Teach concepts to help with patient compliance (laboratory
review)
• Create a class to assist with the transition to dialysis
(patient satisfaction survey)

Teaching at Work

• Study how you deliver your message for efficacy
• Audience: trainees, nurses, dieticians, dialysis
technologists, colleagues
• Learning at lunch: short nursing lectures (medical
knowledge test)
• Create a video for dialysis patients (pretest and posttest)
• Supply handouts to improve medical knowledge (multiple
methods)

Simulation

• Requirement for credentialing organizations
• Audience: trainees, nurses, dieticians, dialysis
technologists, colleagues
• Can be high-level or low-level technology
• Master procedure skills (direct observation)
• Practice patient interaction skills: delivering bad news,
difficult patient (video observation)

Novel Ideas for
Delivering Patient
Care

• Test creative concepts
• Audience: trainees, nurses, dieticians, dialysis
technologists, colleagues
• Measure patient satisfaction after changing clinic structure
(patient satisfaction survey)
• Assess exercise tolerance after starting a dialysis work out
routine (interval analysis)

Novel ideas for delivering care
Innovation can come in many forms.
Examine teaching techniques or delivery of care methods that are new
to the field. For example, increase
the time you spend with patients by
grouping those with similar medical
problems together, such as monthly
peritoneal dialysis visits. This gives
patients a way to connect with others in a similar situation, and it also
allows teaching concepts of care only
once to the group instead of repeatedly in separate patient visits. Assess
whether this improves patients’ satisfaction with their care, their medical
knowledge, or ultimately their outcomes.

Steps to educational research
No matter the practice model, there
are ways to implement educational
research. Innovation and energy for
a project are important, but without
the tools to accomplish the task, no
project will be successful. The process of educational research should
parallel the familiar scientific methods (5).

Step 1: Formulate the question
The research question should be specific, with a measurable outcome.
For example, you might notice that
dialysis patients go through multiple cannulations before starting their
treatment. A research question could
be this: Does staff education about
cannulation improve successful needle placement rates?

Table 2. Educational research outcome measures
Qualitative Measures

Quantitative Measures

Presurvey and postsurvey: opinion

Presurvey and postsurvey: numerical

Patient satisfaction survey

Medical knowledge test

Video observation

Laboratory review

Interval analysis

Patient outcomes

Direct observation

Provider performance

Interview

Chart review
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Step 4: Implement the change
More is not always better. Focus
on finding the most effective tool
to deliver the information. It may
take more than one session to have
the learner retain the information.
For example, it is advisable to give
a lecture and then provide written
language for review. Similarly, teaching patients and having them teach it
back is another effective method to
get repetition and check understanding.

Step 5: Measure the
intervention
Not all changes improve the outcome; in fact, change might make it
worse. Prove that the intervention is
worth the extra effort, and make sure
that the old way is not better. If the
desired outcome is not met, reevaluate the intervention and try again.

Step 6: Share your findings
Most importantly, unless all concerned work together to share their
successes and failures, progress in the
field of nephrology education will
be slow. Similar problems are seen
in many practices, and if ideas for
change can be shared with the community, improvement in the field
will be enhanced (5). There has been
a decline in the number of learners choosing nephrology as a career,
which may be attributed to the style
of presenting subject matter or to a
lack of dedicated mentorship (9).
Optimizing the delivery of curriculum material to enhance understanding might be one way we can lead
more trainees to a career in the field.
An excellent avenue to share
projects is through the ASN Kidney
Week Educational Abstracts Category. This category was developed
in 2008 and is a place for sharing
changes in educational programs that
can make a difference in patients’
lives. These projects can be initiated
and submitted by any part of the care
team. Take time to consider adding a
submission to the category this year.
More information can be found at
the ASN website.
Laura Maursetter, DO, is a member of
the ASN Workforce Committee and assistant professor in the Division of Nephrology at the University of Wisconsin
Madison, where she serves as the associate program director. She is a member
of the ASN Workforce Committee that
is focused on increasing interest in nephrology as a career for trainees.
Mary K. Thompson is a PhD educator in the department of medicine at
the University of Wisconsin-Madison.
She works with fellowships across the
department supporting education and
curricular needs.
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Policy Update
Hill Day 2012: ASN Leaders Put Kidney Disease in
Legislative Spotlight
By Grant Olan and Rachel Shaffer

T

he ASN Council, Public Policy Board, and
Board of Advisors met with legislators on
Capitol Hill as part of the biannual Board of Advisors meeting on April 26, 2012. The second
annual ASN Hill Day provided ASN leaders an
opportunity to talk directly with lawmakers and
House and Senate staff about issues of importance
to ASN and the kidney care community. ASN
leaders met with more than 50 congressional offices, including more than a half-dozen meetings
with senators and representatives themselves, and
were divided into four teams to discuss one of the
following issues:

•

•
•
•

National Institutes of Health (NIH) and National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) funding and investigation of kidney health disparities, including a bill (S.2163) recently introduced by Sen.
Kent Conrad (D-ND) that promotes research
regarding disparities and access to care.
Support for legislation to extend lifetime coverage of immunosuppressive drugs for kidney
transplant recipients (S.1454/H.R.2969).
ASN’s efforts to increase interaction between
the nephrology community and the U.S. Food
and Drug Administration (FDA).
A complex set of issues and upcoming changes
related to the Medicare end stage renal disease
(ESRD) program and the practice of nephrology.

ASN leaders met not only with senators and
representatives from their home states and districts, but also with key members of congressional
committees with jurisdiction over the issues ASN
discussed, either from an “authorizing” perspective (meaning that the committee can tell a certain program or agency what it is allowed to, or
must, do) or from an “appropriations” perspective
(meaning that the committee is in charge of determining how much funding an agency or a program receives).
This Policy Update gives an in-depth description
of the issues for ASN Hill Day 2012, and includes
an article from members of the ASN Transplant
Advisory Group that illustrates why advocating for
legislation to extend lifetime coverage of immunosuppressive drugs was—and continues to be—a
top ASN policy priority.
As noted above, ASN’s collaboration with the
FDA is one of the society’s top policy priorities in
2012. Several ASN leaders discussed this priority
with members of Congress who oversee the FDA.
Although ASN is still in the early stages of outlining this collaborative initiative with the FDA to
protect kidney health, the society received positive
feedback about its goals from members in both the
House and Senate. Stay tuned to Kidney News for

more details about this vitally important initiative
in the coming months.

ASN Addresses NIH Research, Health
Disparities, and S.2163
During office meetings with House and Senate
appropriators and other lawmakers, ASN leaders
discussed the importance of supporting the NIH,
which in turn supports innovative kidney disease
research that will improve patient care, cut costs,
and preserve the investigator pipeline. The bottom
line—funding NIH is a smart investment because
NIH research generates jobs, stimulates the economy, and enables life-saving medical advancements.
ASN leaders spoke about the public health importance and economic benefits of kidney disease
research. ASN supports the work of Congress to
reduce the federal debt in a socially and fiscally responsible manner, which is why we urge continued
investments in medical research. Publicly funded
research supports one of every 500 full-time jobs
in the United States, and every dollar invested
in medical research generates $2.60 of economic
activity. Furthermore, according to a 2010 study,
research funding also generated 487,900 new jobs
nationally and produced more than $68 billion in
new economic activity in the United States.
Most developed countries are dramatically increasing their budgets for medical research. China
in particular is ramping up investments in this
arena. Currently, the United States is the world
leader and can attract the best and brightest investigators from across the globe, but in order to
maintain this position it is critical to protect medical research funding. Without this investment, the
ability to sustain a pipeline of researchers from this
country and abroad—and their future contributions to improving patient care and treatment and
possible cures—will be lost.
Consequently, ASN leaders asked the House
and Senate offices they met with for their support
of $32 billion for the NIH and specifically $2.03
billion for the NIDDK in the fiscal year 2013
budget—the minimum investment necessary to
avoid further loss of promising research and allow
NIH’s and NIDDK’s budgets to keep pace with
the rising cost of conducting biomedical research.
ASN leaders also explained the importance of
health disparities research and requested support
for the Kidney Disease Equitable Access, Prevention,
and Research Act of 2012 (S.2163). Research has
helped physicians understand some of the reasons
why many minority populations are at higher risk
for kidney disease, but without support for additional research we cannot move forward to address
and resolve disparities in kidney care.
Sen. Kent Conrad (D-ND) introduced S.2163
to help resolve inequities in kidney disease health

policy by addressing barriers to transportation,
patient education, and access to insurance. For example, S.2163 would provide key education for
Medicare beneficiaries with stage V chronic kidney
disease (CKD) through medical and clinical staff
at dialysis facilities. Senate bill 2163 would also
allow individuals with kidney failure to maintain
their private insurance by extending the Medicare
Secondary Payer period from 30 to 42 months after they quality for Medicare, which would achieve
important savings for the Medicare program.
Leading up to Hill Day, ASN laid the groundwork on the medical research advocacy front,
including collaborating with the American Society of Pediatric Nephrology (ASPN) to send a
letter supporting kidney disease research to both
the House and Senate appropriations committees that was signed by numerous other members
of the kidney community, representing patients,
providers, and industry. ASN has received positive
feedback regarding the letter, including a request
from the office of Rep. Jeff Flake (R-AZ), who sits
on the House Ways and Means Appropriations
health subcommittee (which has significant influence over the NIH budget) to discuss kidney disease research and the NIDDK budget in particular. While this is a difficult time for Congress to
make spending-related decisions, the importance
of kidney disease research is squarely on the radar
screens of those members with influence.
ASN and ASPN are deeply grateful for the support of the Congressional Kidney Caucus, which
submitted language for inclusion in the report
the House Appropriations Committee submits to
the full House of Representatives highlighting the
importance of kidney disease research across the
NIH and directed at patients of all ages. This report is vitally important, as it explains to Congress
the reasons for including the spending proposals in appropriations bills. In addition, ASN and
ASPN worked with the caucus to include a specific
funding recommendation of $2.03 billion for the
NIDDK budget—the first time a specific budget
level has been supported by the kidney community.
ASN has taken a number of other steps such as:

•
•
•
•

Joining more than 165 organizations in sending
a letter urging Congress to support $32 billion
in funding for NIH.
Involving the ASN membership in a petitionsigning campaign urging the White House to
support more funding for NIH.
Joining more than 900 organizations in sending a letter urging Congress to avert cuts to the
overall Health and Human Services budget.
Launching an ASN membership email campaign to urge their members of Congress to

May 2012 | ASN Kidney News |

support more research funding for NIH. Contact your member at http://capwiz.com/asn/
home/.
ASN is grateful to the society’s leaders for helping
make Hill Day 2012 a success, and the society will
continue to engage lawmakers and their offices in
the months to come as the budget process plays
out and other pieces of legislation important to the
kidney community move forward.

Helping Congress Understand the
Evolving Practice Environment in
Nephrology
Congress made a commitment to save the lives
of people with kidney failure by establishing the
Medicare ESRD program in 1972, a program that
covers all citizens experiencing kidney failure, regardless of age. This essential government program
and the kidney professionals who implement it are
at the forefront of the innovations, system transformations, and pioneering changes that will affect
other areas of health care.
A key goal of ASN Hill Day was informing those
lawmakers with oversight of the Medicare ESRD
program, or those with a history of commitment
to kidney disease and the Medicare ESRD program, of the implications these profound reforms
could have for patients and physicians. In order for
ASN to achieve success in this area, it is crucial
to gain the support of lawmakers who understand
the complexity of these changes, who will support
kidney professionals’ effort to enact change that
focuses on improving care for a vulnerable population, and who will allow time to assess efforts to
reduce costs and measure the quality of care.
ASN representatives discussed four key components of the “evolving practice environment in
nephrology.”
First is the ongoing process of implementing the
Medicare Improvements for Patients and Providers Act (MIPPA), including bundled payments for
dialysis care. At the heart of ASN’s message was
the principle that Congress should avoid future
Medicare payment changes until recently enacted
MIPPA changes are fully implemented. Meaningful cost reductions will succeed only if patient care
remains uncompromised. Evaluating the success of
the program’s experience with bundled payment
systems and pay-for-performance quality programs
will serve as a model for needed changes to other
areas of health care.
Second, it is important for Congress to understand the complexity of addressing the measures
and programs related to improving the quality of
health care. Because nephrology professionals provide care to a highly vulnerable patient population,
achieving this goal requires consistent, evidencebased evaluations of the quality of care provided.
Promoting the use of the same measures across programs is crucial to facilitate consistent care, reduce
unnecessary reporting burdens, and prevent costly
data duplication. ASN is dedicated to helping develop and ensure the consistency of quality metrics
that fulfill these essential standards.
Third, ASN discussed the society’s principles

related to the potential development of integrated
care delivery models. Foremost among these principles (available in full at http://asn-online.org) is
preservation of the patient-physician relationship.
ASN’s advocates addressed the very real potential
that such pilot or demonstration programs could
pave the way to dramatic improvements in kidney
care, but cautioned that establishing successful
ones requires careful consideration of the potential
effects on a vulnerable patient population.
The fourth component of ASN’s message was the
vital need to repeal the flawed sustainable growth
rate and replace it with a sensible alternative. Addressing this fundamentally defective formula is
key to ensuring that patients maintain access to
care, and that physicians can count on the Medicare program to provide payments that accurately
reflect the cost of care.

Making the Case for Lifetime
Immunosuppressive Drug Coverage
Advocating for legislation to extend lifetime coverage
of immunosuppressive drugs (S.1454/H.R.2969) is a
cornerstone of ASN’s public policy and Hill Day 2012
messages. ASN leaders met with more than a dozen
offices, specifically focusing on members of Congress
who supported this bill when it was introduced in
the 111th Congress, but who have not signed onto the
bill in the 112th Congress (the current session). Here,
members of the ASN Transplant Advisory Group Alan
Leichtman, MD, David Cohen, MD, and Chair
Michelle Josephson, MD, outline the history of this
legislation and why it’s the right thing for Congress to
do from every perspective, illustrating the many reasons that this issue is at the top of ASN’s public policy
priorities.
Transplantation, for nearly all suitable transplant candidates, is the preferable and most costeffective treatment for ESRD, and typically provides superior longevity, health, and quality of life
when compared with dialysis. Median 5-year survival is nearly double for patients following renal
transplantation compared with patients who remain on dialysis. For those patients with Medicare
coverage from ESRD, Medicare will cover the costs
of dialysis indefinitely but only the initial costs of a
kidney transplant (1). For most transplant patients
Medicare coverage ends after 36 months, leaving
many patients unable to pay for the immunosuppressive medications required indefinitely to prevent rejection. Consequently, financial hardship
forces many to become non-adherent with their
medical regimens—reducing their doses or discontinuing their immunosuppressive medications entirely. Financial hardship-related non-adherence in
turn leads to rejection, transplant dysfunction with
the associated costs of CKD, and the premature
return to dialysis. Once patients return to dialysis they are again covered by Medicare, at minimal
estimated costs exceeding $82,000 annually compared with approximately $11,000 to maintain a
kidney transplant. It clearly makes neither clinical
nor financial sense to pay indefinitely for the less
efficacious and more expensive treatment, while
denying long-term coverage for the more effective

and less costly alternative.
In addition there is a shortage of kidneys, and
the deficit in the number of kidneys available for
transplantation is exacerbated by the 15 percent of
waitlisted patients seeking repeat transplantation.
With lifetime immunosuppressive drug coverage,
there is little doubt that many transplants would
last longer, resulting in fewer patients returning to
the waiting list for repeat transplantation, and thus
more kidneys would be available for other transplant candidates.
How widespread is this problem? While precise
numbers are hard to come by, a survey conducted
by the United Network for Organ Sharing and the
American Society of Transplantation indicated that
70 percent of kidney transplant programs reported
that many of their patients had an extremely serious or very serious problem paying for their medications, and 68 percent reported deaths or graft
losses attributable to cost-related immunosuppressive medication non-adherence (2). While extending Medicare coverage for immunosuppressive
medications will not entirely solve this problem, it
would help a substantial number of these patients.
Federal expenditures for kidney disease currently cost taxpayers more than $30 billion a year,
about 6 percent of the Medicare budget. Expanded
immunosuppressive medication coverage offers a
more cost-effective way for the federal government
to manage these expenses. For nearly 10 years the
transplant community has lobbied Congress to extend coverage of immunosuppressive medications
for kidney transplant recipients for the lifetime of
the organ. A bill has been introduced in both the
House and Senate to provide for this, and it has
broad bipartisan support. The current lead sponsors are the physician Rep. Michael Burgess (RTX), Rep. Ron Kind (D-WI), Sen. Dick Durbin
(D-IL), and Sen. Thad Cochran (R-MS). The current House Ways and Means Committee Chairman
Dave Camp (R-MI) was the lead sponsor for many
years. ASN will continue to work with a coalition
of transplant organizations to keep the patient immunosuppressive medication coverage extension
bill at the top of many legislative priority lists.
This current policy of paying for a kidney patient’s
transplant but not providing the drugs necessary
to keep the transplant and the patient alive defies
common sense, is life threatening for patients, and
costs the federal government untold millions in
avoidable expenditures. When will common sense
prevail?
Please visit the ASN’s Legislative Action Center (http://capwiz.com/asn/home) and send your
members of Congress a message telling them how
important this bill is for all patients with kidney
disease.
1. Gill JS, Tonelli M. Penny wise, pound foolish?
Coverage limits on immunosuppression after
kidney transplantation. N Engl J Med 2012;
366:586–589.
2. Evans RW, Applegate WH, Briscoe DM, et al.
Cost-related immunosuppressive medication
nonadherence among kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5:2323–2328.
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Leader of ASN Grants Review Committee Named
Editor-in Chief of Kidney International; New Chair Named

A

fter leading the American Society
of Nephrology (ASN) Grants Program for 3 years, Detlef Schlondorff, MD, has been named editor-in-chief
of Kidney International. Under his guidance, the ASN Grants Review Committee
added two new opportunities for career
development grants: the ASN–Association
of Specialty Professors (ASP)–National
Institute of Aging (NIA) Junior Development Grant in Geriatric Nephrology, and
the NephCure Foundation–ASN Research
Grant. Schlondorff was also instrumental
in expanding the ASN Student Scholar
Grant Program and launching the new
ASN Research Fellowship Program, which
will fund its first 10 fellows later this year.
The ASN Grants Program distributes
more than $3 million each year in research
funding to medical students, fellows, new
investigators, and established investigators.
Last year ASN awarded a total of 31 research grants.
“Dr. Schlondorff has been instrumental in maintaining the high caliber of
quality of the ASN Grants Program, and
expanding the program to reach more researchers,” said ASN Past-President Joseph

Bonventre, MD, PhD, FASN. “I am
particularly impressed by his ability to
manage an increasingly complex grants
portfolio with increasing numbers of applications, and his leadership in strengthening ASN’s partnerships with the Halpin
Foundation, the NephCure Foundation,
ASP, and NIA.”
In addition to his success overseeing
the ASN Grants Program, Schlondorff
has a long list of academic and professional achievements. He currently serves
as visiting professor of medicine at Mount
Sinai School of Medicine, where he leads
an active research laboratory. Schlondorff has authored more than 300 peerreviewed original and review articles
and book chapters, and has edited two
textbooks. He is a member of numerous
professional societies and has received the
Franz Volhard Medal from the German
Nephrology Society and the International
Prize Luis Hernando from the Spanish
Renal Foundation.
Schlondorff received his medical degree at Ludwig Maximilians University
in Munich, and continued his training
in Germany and at the Albert Einstein

College of Medicine and Montefiore
Hospital in New York. He was professor
of medicine and chief of the nephrology
division at the Albert Einstein College of
Medicine from 1988 to 1993, when he
became chair and professor of medicine
and director of the University Medical
Policlinic Hospital Innenstadt of the Ludwig Maximillians University and eventually professor emeritus in 2007.
ASN is pleased to announce that Roy
Zent, MD, PhD, will succeed Schlon-

dorff as chair of the ASN Grants Review
Committee. Zent is professor of medicine
at Vanderbilt University School of Medicine and has served on the Grants Review
Committee since 2008. “I am confident
that Dr. Zent will provide excellent leadership as ASN continues to expand and
innovate its grants program,” said ASN
President Ronald Falk, MD, FASN.
“In particular, I’m excited that Dr. Zent
agreed to help launch the ASN Research
Fellowship Program this year.”

ASN Research Grants
• Career Development Grants for New Investigators
• Carl W. Gottschalk Research Scholar Grant (established in 1996)
• John Merrill Grant in Transplantation (established in 2001)
• The Halpin Foundation–ASN Research Grant (established in 2006)
• Normal Siegel Research Scholar Grant (established in 2007)
• The NephCure Foundation–ASN Research Grant (established in 2012)
• ASN-ASP-NIA Junior Development Grant in Geriatric Nephrology
(established in 2011)
• M. James Scherbenske Grants for Established Investigators (established
in 1996)
• Student Scholar Grants (established in 2000)
• Research Fellowships (established in 2012)
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